{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:04:37Z","timestamp":1793325877854,"version":"4.5.0"},"reference-count":335,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M770208"],"award-info":[{"award-number":["2025M770208"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32501198"],"award-info":[{"award-number":["32501198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304399"],"award-info":[{"award-number":["82304399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304395"],"award-info":[{"award-number":["82304395"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204297"],"award-info":[{"award-number":["82204297"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32101145"],"award-info":[{"award-number":["32101145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Qimingxing\" Research Fund for Young Talents of West China Hospital","award":["HXQMX0030"],"award-info":[{"award-number":["HXQMX0030"]}]},{"name":"Qimingxing\" Research Fund for Young Talents of West China Hospital","award":["HXQMX0110"],"award-info":[{"award-number":["HXQMX0110"]}]},{"name":"Qimingxing\" Research Fund for Young Talents of West China Hospital","award":["HXQMX0109"],"award-info":[{"award-number":["HXQMX0109"]}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024NSFSC1739"],"award-info":[{"award-number":["2024NSFSC1739"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024NSFSC1665"],"award-info":[{"award-number":["2024NSFSC1665"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovation Group Project from Science & Technology Department of Sichuan Province","award":["2023NSFSC1993"],"award-info":[{"award-number":["2023NSFSC1993"]}],"id":[{"id":"https:\/\/ror.org\/04323m874","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02712-8","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:23:56Z","timestamp":1784269436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Breaking barriers: nano-boosted drug delivery systems in overcoming the defenses of pancreatic cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Yujia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"3","key":"2712_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"10242","key":"2712_CR2","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008\u201320.","journal-title":"Lancet"},{"issue":"1","key":"2712_CR3","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2(1):16022.","journal-title":"Nat Rev Dis Primers"},{"key":"2712_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jconrel.2020.01.041","volume":"320","author":"Y-J Li","year":"2020","unstructured":"Li Y, Wu J, Wang J, Xiang D. Emerging nanomedicine-based strategies for preventing metastasis of pancreatic cancer. J Controlled Release. 2020;320:105\u201311.","journal-title":"J Controlled Release"},{"issue":"11","key":"2712_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41575-021-00486-6","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Zeh HJ, Kang R, Kroemer G, Tang D. Cell death in pancreatic cancer: from pathogenesis to therapy. Nat Rev Gastroenterol Hepatol. 2021;18(11):804\u201323.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2712_CR6","doi-asserted-by":"publisher","first-page":"119421","DOI":"10.1016\/j.biomaterials.2019.119421","volume":"222","author":"M Broekgaarden","year":"2019","unstructured":"Broekgaarden M, Anbil S, Bulin A-L, Obaid G, Mai Z, Baglo Y, et al. Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer. Biomaterials. 2019;222:119421.","journal-title":"Biomaterials"},{"issue":"48","key":"2712_CR7","doi-asserted-by":"publisher","first-page":"40733","DOI":"10.1021\/acsnano.5c14753","volume":"19","author":"AE Nel","year":"2025","unstructured":"Nel AE, Luo L, Liao Y-P, Wang X. Reprogramming Immunosuppressive Niches and the Cancer Immunity Cycle in Pancreatic Cancer with Neoantigen mRNA Plus Immune Adjuvant Nanocarrier Strategies. ACS Nano. 2025;19(48):40733\u201345.","journal-title":"ACS Nano"},{"key":"2712_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.aanat.2018.09.008","volume":"221","author":"BM Henry","year":"2019","unstructured":"Henry BM, Skinningsrud B, Saganiak K, P\u0119kala PA, Walocha JA, Tomaszewski KA. Development of the human pancreas and its vasculature \u2014 An integrated review covering anatomical, embryological, histological, and molecular aspects. Ann Anat - Anatomischer Anzeiger. 2019;221:115\u201324.","journal-title":"Ann Anat - Anatomischer Anzeiger"},{"issue":"20","key":"2712_CR9","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1056\/NEJMp1508811","volume":"373","author":"B Vogelstein","year":"2015","unstructured":"Vogelstein B, Kinzler KW. The Path to CancerProcess \u2014 Three Strikes and You\u2019re Out. N Engl J Med. 2015;373(20):1895\u20138","journal-title":"N Engl J Med"},{"issue":"7722","key":"2712_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-018-0481-8","volume":"561","author":"AP Makohon-Moore","year":"2018","unstructured":"Makohon-Moore AP, Matsukuma K, Zhang M, Reiter JG, Gerold JM, Jiao Y, et al. Precancerous neoplastic cells can move through the pancreatic ductal system. Nature. 2018;561(7722):201\u20135.","journal-title":"Nature"},{"issue":"2","key":"2712_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.canlet.2006.09.007","volume":"249","author":"F Sch\u00f6nleben","year":"2007","unstructured":"Sch\u00f6nleben F, Qiu W, Bruckman KC, Ciau NT, Li X, Lauerman MH, et al. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm\/carcinoma (IPMN\/IPMC) of the pancreas. Cancer Lett. 2007;249(2):242\u20138.","journal-title":"Cancer Lett"},{"issue":"4","key":"2712_CR12","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1152\/physrev.00042.2019","volume":"100","author":"E Hessmann","year":"2020","unstructured":"Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, et al. Microenvironmental Determinants of Pancreatic Cancer. Physiol Rev. 2020;100(4):1707\u201351.","journal-title":"Physiol Rev"},{"issue":"5","key":"2712_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2159-8290.CD-19-1353","volume":"10","author":"E Helms","year":"2020","unstructured":"Helms E, Onate MK, Sherman MH. Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment. Cancer Discov. 2020;10(5):648\u201356.","journal-title":"Cancer Discov"},{"issue":"5","key":"2712_CR14","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/anie.200802585","volume":"48","author":"K Riehemann","year":"2009","unstructured":"Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine \u2014 Challenge and Perspectives. Angew Chem Int Ed. 2009;48(5):872\u201397.","journal-title":"Angew Chem Int Ed"},{"issue":"1","key":"2712_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20\u201337.","journal-title":"Nat Rev Cancer"},{"key":"2712_CR16","doi-asserted-by":"crossref","unstructured":"Kim Betty YS, Rutka James T, Chan Warren CW, Current concepts. N Engl J Med. 2010;363(25):2434\u201343.","DOI":"10.1056\/NEJMra0912273"},{"issue":"12","key":"2712_CR17","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrclinonc.2016.119","volume":"13","author":"PP Adiseshaiah","year":"2016","unstructured":"Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol. 2016;13(12):750\u201365.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10018","key":"2712_CR18","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545\u201357.","journal-title":"Lancet"},{"issue":"18","key":"2712_CR19","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"3","key":"2712_CR20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.7150\/thno.64805","volume":"12","author":"L Liu","year":"2022","unstructured":"Liu L, Kshirsagar PG, Gautam SK, Gulati M, Wafa EI, Christiansen JC, et al. Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. Theranostics. 2022;12(3):1030\u201360.","journal-title":"Theranostics"},{"issue":"8","key":"2712_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487\u2013505.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2712_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","volume":"18","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Beatty GL. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu Rev Pathol. 2023;18:123\u201348.","journal-title":"Annu Rev Pathol"},{"key":"2712_CR23","doi-asserted-by":"publisher","first-page":"1287459","DOI":"10.3389\/fimmu.2024.1287459","volume":"15","author":"C Hartupee","year":"2024","unstructured":"Hartupee C, Nagalo BM, Chabu CY, Tesfay MZ, Coleman-Barnett J, West JT, et al. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Front Immunol. 2024;15:1287459.","journal-title":"Front Immunol"},{"issue":"2","key":"2712_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41568-022-00530-w","volume":"23","author":"SR Hingorani","year":"2023","unstructured":"Hingorani SR. Epithelial and stromal co-evolution and complicity in pancreatic cancer. Nat Rev Cancer. 2023;23(2):57\u201377.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2712_CR25","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9(8):1102\u201323.","journal-title":"Cancer Discov"},{"issue":"27","key":"2712_CR26","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J Clin Oncol. 2020;38(27):3185\u201394.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2712_CR27","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","volume":"3","author":"D Lavie","year":"2022","unstructured":"Lavie D, Ben-Shmuel A, Erez N, Scherz-Shouval R. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 2022;3(7):793\u2013807.","journal-title":"Nat Cancer"},{"issue":"2","key":"2712_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1158\/2159-8290.CD-21-0601","volume":"12","author":"EJ Helms","year":"2022","unstructured":"Helms EJ, Berry MW, Chaw RC, DuFort CC, Sun D, Onate MK, et al. Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer-Associated Fibroblasts. Cancer Discov. 2022;12(2):484\u2013501.","journal-title":"Cancer Discov"},{"issue":"3","key":"2712_CR29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579\u201396.","journal-title":"J Exp Med"},{"issue":"1","key":"2712_CR30","doi-asserted-by":"publisher","first-page":"10534","DOI":"10.1038\/s41467-024-54975-8","volume":"15","author":"L Veghini","year":"2024","unstructured":"Veghini L, Pasini D, Fang R, Delfino P, Filippini D, Neander C, et al. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. Nat Commun. 2024;15(1):10534.","journal-title":"Nat Commun"},{"issue":"8","key":"2712_CR31","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nm.4123","volume":"22","author":"H Jiang","year":"2016","unstructured":"Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22(8):851\u201360.","journal-title":"Nat Med"},{"issue":"2","key":"2712_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, et al. IL1-induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9(2):282\u2013301.","journal-title":"Cancer Discov"},{"key":"2712_CR33","doi-asserted-by":"crossref","unstructured":"Jiang B, Zhou L, Lu J, Wang Y, Liu C, You L et al. Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides? Front Oncol. 2020;10:2020.","DOI":"10.3389\/fonc.2020.576399"},{"issue":"9","key":"2712_CR34","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1136\/gutjnl-2015-309304","volume":"64","author":"A Neesse","year":"2015","unstructured":"Neesse A, Alg\u00fcl H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64(9):1476.","journal-title":"Gut"},{"key":"2712_CR35","doi-asserted-by":"crossref","unstructured":"Nia HT, Munn LL, Jain RK. Physical traits of cancer. Science. 2020;370(6516):eaaz0868.","DOI":"10.1126\/science.aaz0868"},{"issue":"43","key":"2712_CR36","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109(43):17561\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2712_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2712_CR38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1535-7163.MCT-14-0366","volume":"14","author":"KN Sugahara","year":"2015","unstructured":"Sugahara KN, Braun GB, de Mendoza TH, Kotamraju VR, French RP, Lowy AM, et al. Tumor-penetrating iRGD peptide inhibits metastasis. Mol Cancer Ther. 2015;14(1):120\u20138.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2712_CR39","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1038\/s41592-024-02564-4","volume":"22","author":"HT Nia","year":"2025","unstructured":"Nia HT, Munn LL, Jain RK. Probing the physical hallmarks of cancer. Nat Methods. 2025;22(9):1800\u201318.","journal-title":"Nat Methods"},{"issue":"17","key":"2712_CR40","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","volume":"31","author":"RK Jain","year":"2013","unstructured":"Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31(17):2205\u201318.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2712_CR41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","volume":"4","author":"T Stylianopoulos","year":"2018","unstructured":"Stylianopoulos T, Munn LL, Jain RK. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside. Trends Cancer. 2018;4(4):292\u2013319.","journal-title":"Trends Cancer"},{"key":"2712_CR42","doi-asserted-by":"publisher","first-page":"787485","DOI":"10.3389\/fcell.2021.787485","volume":"9","author":"P Maneshi","year":"2021","unstructured":"Maneshi P, Mason J, Dongre M, \u00d6hlund D. Targeting tumor-stromal interactions in pancreatic cancer: impact of collagens and mechanical traits. Front Cell Dev Biol. 2021;9:787485.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2712_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40169-019-0226-9","volume":"8","author":"SK Daniel","year":"2019","unstructured":"Daniel SK, Sullivan KM, Labadie KP, Pillarisetty VG. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. Clin Transl Med. 2019;8(1):10.","journal-title":"Clin Transl Med"},{"issue":"6282","key":"2712_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aaf4405","volume":"352","author":"EB Rankin","year":"2016","unstructured":"Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352(6282):175\u201380.","journal-title":"Science"},{"issue":"12","key":"2712_CR45","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","volume":"2","author":"L Schito","year":"2016","unstructured":"Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer. 2016;2(12):758\u201370.","journal-title":"Trends Cancer"},{"issue":"23","key":"2712_CR46","doi-asserted-by":"publisher","first-page":"6488","DOI":"10.1039\/C6CS00616G","volume":"45","author":"W Fan","year":"2016","unstructured":"Fan W, Huang P, Chen X. Overcoming the Achilles\u2019 heel of photodynamic therapy. Chem Soc Rev. 2016;45(23):6488\u2013519.","journal-title":"Chem Soc Rev"},{"issue":"32","key":"2712_CR47","doi-asserted-by":"publisher","first-page":"13557","DOI":"10.1002\/anie.202004894","volume":"59","author":"X Pan","year":"2020","unstructured":"Pan X, Wang W, Huang Z, Liu S, Guo J, Zhang F, et al. MOF-derived double-layer hollow nanoparticles with oxygen generation ability for multimodal imaging-guided sonodynamic therapy. Angew Chem Int Ed Engl. 2020;59(32):13557\u201361.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"2712_CR48","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10238-024-01501-1","volume":"24","author":"J Ciep\u0142a","year":"2024","unstructured":"Ciep\u0142a J, Smolarczyk R. Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies. Clin Exp Med. 2024;24(1):235.","journal-title":"Clin Exp Med"},{"issue":"1","key":"2712_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","volume":"14","author":"J Tao","year":"2021","unstructured":"Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol. 2021;14(1):14.","journal-title":"J Hematol Oncol"},{"key":"2712_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.biomaterials.2014.12.028","volume":"46","author":"X Zhao","year":"2015","unstructured":"Zhao X, Li F, Li Y, Wang H, Ren H, Chen J, et al. Co-delivery of HIF1\u03b1 siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Biomaterials. 2015;46:13\u201325.","journal-title":"Biomaterials"},{"issue":"21","key":"2712_CR51","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1021\/acs.chemrev.1c00381","volume":"121","author":"TC Pham","year":"2021","unstructured":"Pham TC, Nguyen VN, Choi Y, Lee S, Yoon J. Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy. Chem Rev. 2021;121(21):13454\u2013619.","journal-title":"Chem Rev"},{"issue":"6","key":"2712_CR52","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","volume":"38","author":"AS Bear","year":"2020","unstructured":"Bear AS, Vonderheide RH, O\u2019Hara MH. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell. 2020;38(6):788\u2013802.","journal-title":"Cancer Cell"},{"issue":"1","key":"2712_CR53","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-023-02935-3","volume":"43","author":"W Luo","year":"2024","unstructured":"Luo W, Wen T, Qu X. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept. J Exp Clin Cancer Res. 2024;43(1):8.","journal-title":"J Exp Clin Cancer Res"},{"key":"2712_CR54","doi-asserted-by":"publisher","first-page":"613815","DOI":"10.3389\/fimmu.2020.613815","volume":"11","author":"ZC Schmiechen","year":"2020","unstructured":"Schmiechen ZC, Stromnes IM. Mechanisms governing immunotherapy resistance in pancreatic ductal adenocarcinoma. Front Immunol. 2020;11:613815.","journal-title":"Front Immunol"},{"issue":"3","key":"2712_CR55","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","volume":"37","author":"S Hegde","year":"2020","unstructured":"Hegde S, Krisnawan VE, Herzog BH, Zuo C, Breden MA, Knolhoff BL, et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell. 2020;37(3):289\u2013e3079.","journal-title":"Cancer Cell"},{"issue":"1","key":"2712_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","volume":"17","author":"P Farhangnia","year":"2024","unstructured":"Farhangnia P, Khorramdelazad H, Nickho H, Delbandi AA. Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol. 2024;17(1):40.","journal-title":"J Hematol Oncol"},{"key":"2712_CR57","doi-asserted-by":"publisher","first-page":"15095","DOI":"10.1038\/ncomms15095","volume":"8","author":"JL Carstens","year":"2017","unstructured":"Carstens JL, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A, et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017;8:15095.","journal-title":"Nat Commun"},{"issue":"50","key":"2712_CR58","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(50):20212\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2712_CR59","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1053\/j.gastro.2022.02.024","volume":"162","author":"CJ Garcia Garcia","year":"2022","unstructured":"Garcia Garcia CJ, Huang Y, Fuentes NR, Turner MC, Monberg ME, Lin D, et al. Stromal HIF2 regulates immune suppression in the pancreatic cancer microenvironment. Gastroenterology. 2022;162(7):2018\u201331.","journal-title":"Gastroenterology"},{"key":"2712_CR60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 2020;71:47\u201358.","journal-title":"Annu Rev Med"},{"issue":"18","key":"2712_CR61","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","volume":"25","author":"DT Le","year":"2019","unstructured":"Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, et al. Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study). Clin Cancer Res. 2019;25(18):5493\u2013502.","journal-title":"Clin Cancer Res"},{"key":"2712_CR62","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.3389\/fimmu.2019.01848","volume":"10","author":"A Marchini","year":"2019","unstructured":"Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J. Immune conversion of tumor microenvironment by oncolytic viruses: the protoparvovirus H-1PV case study. Front Immunol. 2019;10:1848.","journal-title":"Front Immunol"},{"key":"2712_CR63","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fimmu.2020.00223","volume":"11","author":"RM Zemek","year":"2020","unstructured":"Zemek RM, Chin WL, Nowak AK, Millward MJ, Lake RA, Lesterhuis WJ. Sensitizing the tumor microenvironment to immune checkpoint therapy. Front Immunol. 2020;11:223.","journal-title":"Front Immunol"},{"issue":"12","key":"2712_CR64","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/s43018-022-00470-2","volume":"3","author":"F Cappellesso","year":"2022","unstructured":"Cappellesso F, Orban MP, Shirgaonkar N, Berardi E, Serneels J, Neveu MA, et al. Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer. Nat Cancer. 2022;3(12):1464\u201383.","journal-title":"Nat Cancer"},{"issue":"5","key":"2712_CR65","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651\u201362.","journal-title":"Lancet Oncol"},{"key":"2712_CR66","doi-asserted-by":"crossref","unstructured":"Waters AM, Der CJ. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med. 2018;8(9):a031435.","DOI":"10.1101\/cshperspect.a031435"},{"issue":"1","key":"2712_CR67","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-024-01613-x","volume":"17","author":"J Wang","year":"2024","unstructured":"Wang J, Yang J, Narang A, He J, Wolfgang C, Li K, et al. Consensus, debate, and prospective on pancreatic cancer treatments. J Hematol Oncol. 2024;17(1):92.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2712_CR68","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40291-020-00472-9","volume":"24","author":"C Vitellius","year":"2020","unstructured":"Vitellius C, Griveaux O, Morvant B, Pedrono E, Venara A, Ingster O, et al. Impact of driver mutations on the evolution of isolated metachronous lung metastasis of pancreatic ductal adenocarcinoma. Mol Diagn Ther. 2020;24(4):443\u20139.","journal-title":"Mol Diagn Ther"},{"issue":"7540","key":"2712_CR69","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495\u2013501.","journal-title":"Nature"},{"issue":"1","key":"2712_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1\u201310.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2712_CR71","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","volume":"11","author":"O Hamarsheh Sa, Gro\u00df","year":"2020","unstructured":"Hamarsheh Sa, Gro\u00df O, Brummer T, Zeiser R. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun. 2020;11(1):5439.","journal-title":"Nat Commun"},{"issue":"6","key":"2712_CR72","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jcmgh.2022.02.016","volume":"13","author":"A Velez-Delgado","year":"2022","unstructured":"Velez-Delgado A, Donahue KL, Brown KL, Du W, Irizarry-Negron V, Menjivar RE, et al. Extrinsic KRAS Signaling Shapes the Pancreatic Microenvironment Through Fibroblast Reprogramming. Cell Mol Gastroenterol Hepatol. 2022;13(6):1673\u201399.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"3","key":"2712_CR73","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/d41573-023-00015-x","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A. The KRAS crowd targets its next cancer mutations. Nat Rev Drug Discov. 2023;22(3):167\u201371.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2712_CR74","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024;14(6):994\u20131017.","journal-title":"Cancer Discov"},{"issue":"5","key":"2712_CR75","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","volume":"25","author":"P Lito","year":"2014","unstructured":"Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014;25(5):697\u2013710.","journal-title":"Cancer Cell"},{"issue":"6","key":"2712_CR76","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00280-015-2730-y","volume":"75","author":"S Kordes","year":"2015","unstructured":"Kordes S, Kl\u00fcmpen HJ, Weterman MJ, Schellens JH, Richel DJ, Wilmink JW. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2015;75(6):1135\u201341.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"2712_CR77","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","volume":"83","author":"J Murai","year":"2023","unstructured":"Murai J, Pommier Y. BRCAness, homologous recombination deficiencies, and synthetic lethality. Cancer Res. 2023;83(8):1173\u20134.","journal-title":"Cancer Res"},{"issue":"8","key":"2712_CR78","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1021\/acs.molpharmaceut.0c00247","volume":"17","author":"MI Confeld","year":"2020","unstructured":"Confeld MI, Mamnoon B, Feng L, Jensen-Smith H, Ray P, Froberg J, et al. Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors. Mol Pharm. 2020;17(8):2849\u201363.","journal-title":"Mol Pharm"},{"key":"2712_CR79","doi-asserted-by":"publisher","first-page":"119907","DOI":"10.1016\/j.biomaterials.2020.119907","volume":"241","author":"J Feng","year":"2020","unstructured":"Feng J, Xu M, Wang J, Zhou S, Liu Y, Liu S, et al. Sequential delivery of nanoformulated \u03b1-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer. Biomaterials. 2020;241:119907.","journal-title":"Biomaterials"},{"issue":"49","key":"2712_CR80","doi-asserted-by":"publisher","first-page":"2206765","DOI":"10.1002\/adma.202206765","volume":"34","author":"X Kang","year":"2022","unstructured":"Kang X, Bu F, Feng W, Liu F, Yang X, Li H, et al. Dual-Cascade Responsive Nanoparticles Enhance Pancreatic Cancer Therapy by Eliminating Tumor-Resident Intracellular Bacteria. Adv Mater. 2022;34(49):2206765.","journal-title":"Adv Mater"},{"key":"2712_CR81","doi-asserted-by":"publisher","first-page":"122949","DOI":"10.1016\/j.cej.2019.122949","volume":"382","author":"L Xing","year":"2020","unstructured":"Xing L, Li X, Xing Z, Li F, Shen M, Wang H, et al. Silica\/gold nanoplatform combined with a thermosensitive gel for imaging-guided interventional therapy in PDX of pancreatic cancer. Chem Eng J. 2020;382:122949.","journal-title":"Chem Eng J"},{"issue":"2","key":"2712_CR82","first-page":"2176","volume":"13","author":"J Lang","year":"2019","unstructured":"Lang J, Zhao X, Wang X, Zhao Y, Li Y, Zhao R, et al. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1\u03b1 Inhibitor Impairs Pancreatic Tumor Growth. ACS Nano. 2019;13(2):2176\u201389.","journal-title":"ACS Nano"},{"key":"2712_CR83","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.biomaterials.2017.05.030","volume":"139","author":"H Li","year":"2017","unstructured":"Li H, Wang P, Deng Y, Zeng M, Tang Y, Zhu W-H, et al. Combination of active targeting, enzyme-triggered release and fluorescent dye into gold nanoclusters for endomicroscopy-guided photothermal\/photodynamic therapy to pancreatic ductal adenocarcinoma. Biomaterials. 2017;139:30\u20138.","journal-title":"Biomaterials"},{"issue":"1","key":"2712_CR84","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1021\/acsnano.9b03978","volume":"14","author":"Y Xie","year":"2020","unstructured":"Xie Y, Hang Y, Wang Y, Sleightholm R, Prajapati DR, Bader J, et al. Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA\/siRNA Nanotherapy. ACS Nano. 2020;14(1):255\u201371.","journal-title":"ACS Nano"},{"key":"2712_CR85","doi-asserted-by":"crossref","unstructured":"Kim J, Cho H, Lim DK, Joo MK, Kim K. Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors. Int J Mol Sci. 2023;24(12):10082.","DOI":"10.3390\/ijms241210082"},{"issue":"12Part1","key":"2712_CR86","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. Cancer Res. 1986;46(12Part1):6387\u201392.","journal-title":"Cancer Res"},{"issue":"3","key":"2712_CR87","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s44222-024-00154-9","volume":"2","author":"LNM Nguyen","year":"2024","unstructured":"Nguyen LNM, Ngo W, Lin ZP, Sindhwani S, MacMillan P, Mladjenovic SM, et al. The mechanisms of nanoparticle delivery to solid tumours. Nat Rev Bioeng. 2024;2(3):201\u201313.","journal-title":"Nat Rev Bioeng"},{"issue":"12","key":"2712_CR88","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nnano.2011.166","volume":"6","author":"H Cabral","year":"2011","unstructured":"Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815\u201323.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"2712_CR89","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","volume":"9","author":"D Rosenblum","year":"2018","unstructured":"Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410.","journal-title":"Nat Commun"},{"issue":"392","key":"2712_CR90","doi-asserted-by":"publisher","first-page":"eaal0225","DOI":"10.1126\/scitranslmed.aal0225","volume":"9","author":"MA Miller","year":"2017","unstructured":"Miller MA, Chandra R, Cuccarese MF, Pfirschke C, Engblom C, Stapleton S, et al. Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts. Sci Transl Med. 2017;9(392):eaal0225.","journal-title":"Sci Transl Med"},{"key":"2712_CR91","doi-asserted-by":"crossref","unstructured":"Yang M, Suzuki R, Koseki Y, Kodera S, Saijo K, Kawakami H et al. Overcoming stromal barriers in pancreatic cancer via size-engineered carrier-free nano-prodrugs. RSC Pharm. 2026:3(3):694\u2013700.","DOI":"10.1039\/D5PM00364D"},{"issue":"2","key":"2712_CR92","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3892\/or.2017.5718","volume":"38","author":"Z Li","year":"2017","unstructured":"Li Z, Tan S, Li S, Shen Q, Wang K. Cancer drug delivery in the nano era: An overview and perspectives (Review). Oncol Rep. 2017;38(2):611\u201324.","journal-title":"Oncol Rep"},{"key":"2712_CR93","doi-asserted-by":"publisher","first-page":"120571","DOI":"10.1016\/j.ijpharm.2021.120571","volume":"601","author":"D Guimar\u00e3es","year":"2021","unstructured":"Guimar\u00e3es D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021;601:120571.","journal-title":"Int J Pharm"},{"issue":"2","key":"2712_CR94","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1021\/acsnano.5b07781","volume":"10","author":"X Liu","year":"2016","unstructured":"Liu X, Situ A, Kang Y, Villabroza KR, Liao Y, Chang CH, et al. Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer. ACS Nano. 2016;10(2):2702\u201315.","journal-title":"ACS Nano"},{"issue":"1","key":"2712_CR95","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Delivery Rev. 2013;65(1):36\u201348.","journal-title":"Adv Drug Delivery Rev"},{"issue":"1","key":"2712_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0168-3659(00)00339-4","volume":"70","author":"KS Soppimath","year":"2001","unstructured":"Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Controlled Release. 2001;70(1):1\u201320.","journal-title":"J Controlled Release"},{"issue":"1","key":"2712_CR97","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","volume":"9","author":"B Wang","year":"2024","unstructured":"Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y, et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther. 2024;9(1):200.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"2712_CR98","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","volume":"124","author":"MA Beach","year":"2024","unstructured":"Beach MA, Nayanathara U, Gao Y, Zhang C, Xiong Y, Wang Y, et al. Polymeric Nanoparticles for Drug Delivery. Chem Rev. 2024;124(9):5505\u2013616.","journal-title":"Chem Rev"},{"issue":"35","key":"2712_CR99","doi-asserted-by":"publisher","first-page":"9340","DOI":"10.1016\/j.biomaterials.2010.08.010","volume":"31","author":"M Vandana","year":"2010","unstructured":"Vandana M, Sahoo SK. Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. Biomaterials. 2010;31(35):9340\u201356.","journal-title":"Biomaterials"},{"issue":"5","key":"2712_CR100","doi-asserted-by":"publisher","first-page":"1701070","DOI":"10.1002\/advs.201701070","volume":"5","author":"X He","year":"2018","unstructured":"He X, Chen X, Liu L, Zhang Y, Lu Y, Zhang Y, et al. Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy. Adv Sci. 2018;5(5):1701070.","journal-title":"Adv Sci"},{"issue":"10","key":"2712_CR101","first-page":"2005","volume":"8","author":"A Thakkar","year":"2018","unstructured":"Thakkar A, Desai P, Chenreddy S, Modi J, Thio A, Khamas W, et al. Novel nano-drug combination therapeutic regimen demonstrates significant efficacy in the transgenic mouse model of pancreatic ductal adenocarcinoma. Am J Cancer Res. 2018;8(10):2005\u201319.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2712_CR102","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/10717544.2021.2018521","volume":"29","author":"X Zeng","year":"2022","unstructured":"Zeng X, Xin Z, Qikang T, Xiaoke T, Ning S, Min Y, et al. Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer. Drug Delivery. 2022;29(1):89\u201398.","journal-title":"Drug Delivery"},{"issue":"3","key":"2712_CR103","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1021\/acs.chemrev.8b00401","volume":"119","author":"N Zhao","year":"2019","unstructured":"Zhao N, Yan L, Zhao X, Chen X, Li A, Zheng D, et al. Versatile Types of Organic\/Inorganic Nanohybrids: From Strategic Design to Biomedical Applications. Chem Rev. 2019;119(3):1666\u2013762.","journal-title":"Chem Rev"},{"issue":"6","key":"2712_CR104","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1039\/D2CS00352J","volume":"52","author":"Z Pei","year":"2023","unstructured":"Pei Z, Lei H, Cheng L. Bioactive inorganic nanomaterials for cancer theranostics. Chem Soc Rev. 2023;52(6):2031\u201381.","journal-title":"Chem Soc Rev"},{"issue":"3","key":"2712_CR105","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jconrel.2012.05.005","volume":"161","author":"F Pittella","year":"2012","unstructured":"Pittella F, Miyata K, Maeda Y, Suma T, Watanabe S, Chen Q, et al. Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate\/charge-conversional polymer hybrid nanoparticles. J Controlled Release. 2012;161(3):868\u201374.","journal-title":"J Controlled Release"},{"issue":"27","key":"2712_CR106","doi-asserted-by":"publisher","first-page":"8217","DOI":"10.1021\/acs.nanolett.4c01534","volume":"24","author":"R Prasad","year":"2024","unstructured":"Prasad R, Jyothi VGS, Kommineni N, Bulusu RT, Mendes BB, Lovell JF, et al. Biomimetic Ghost Nanomedicine-Based Optotheranostics for Cancer. Nano Lett. 2024;24(27):8217\u201331.","journal-title":"Nano Lett"},{"issue":"5","key":"2712_CR107","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1021\/acs.accounts.9b00079","volume":"52","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang Z, Gu Z. Bioinspired and Biomimetic Nanomedicines. Acc Chem Res. 2019;52(5):1255\u201364.","journal-title":"Acc Chem Res"},{"key":"2712_CR108","doi-asserted-by":"publisher","first-page":"101733","DOI":"10.1016\/j.nantod.2022.101733","volume":"48","author":"Q Wang","year":"2023","unstructured":"Wang Q, Wang Z, Li Z, Li D, He F, Wang K, et al. Biomimetic camouflaged nanoparticle-based folfirinox platform for optimizing clinical pancreatic cancer treatment. Nano Today. 2023;48:101733.","journal-title":"Nano Today"},{"issue":"1","key":"2712_CR109","doi-asserted-by":"publisher","first-page":"2304824","DOI":"10.1002\/smll.202304824","volume":"20","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Xu R-H, Dai Y, Nanoghosts. Harnessing Mesenchymal Stem Cell Membrane for Construction of Drug Delivery Platforms Via Optimized Biomimetics. Small. 2024;20(1):2304824.","journal-title":"Small"},{"key":"2712_CR110","first-page":"283","volume":"47","author":"Q-C Yang","year":"2025","unstructured":"Yang Q-C, Wang Y-Y, Wang S, Song A, Wang W-D, Zhang L, et al. Engineered bacterial membrane biomimetic covalent organic framework as nano-immunopotentiator for cancer immunotherapy. Bioact Mater. 2025;47:283\u201394.","journal-title":"Bioact Mater"},{"key":"2712_CR111","first-page":"449","volume":"20","author":"K Ying","year":"2023","unstructured":"Ying K, Zhu Y, Wan J, Zhan C, Wang Y, Xie B, et al. Macrophage membrane-biomimetic adhesive polycaprolactone nanocamptothecin for improving cancer-targeting efficiency and impairing metastasis. Bioact Mater. 2023;20:449\u201362.","journal-title":"Bioact Mater"},{"issue":"4","key":"2712_CR112","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.1021\/acsnano.2c00893","volume":"16","author":"Y Miao","year":"2022","unstructured":"Miao Y, Yang Y, Guo L, Chen M, Zhou X, Zhao Y, et al. Cell Membrane-Camouflaged Nanocarriers with Biomimetic Deformability of Erythrocytes for Ultralong Circulation and Enhanced Cancer Therapy. ACS Nano. 2022;16(4):6527\u201340.","journal-title":"ACS Nano"},{"issue":"3","key":"2712_CR113","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1021\/acsami.0c19259","volume":"13","author":"L Li","year":"2021","unstructured":"Li L, Fu J, Wang X, Chen Q, Zhang W, Cao Y, et al. Biomimetic Nanoplatelets as a Targeted Drug Delivery Platform for Breast Cancer Theranostics. ACS Appl Mater Interfaces. 2021;13(3):3605\u201321.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"41","key":"2712_CR114","doi-asserted-by":"publisher","first-page":"2406483","DOI":"10.1002\/adfm.202406483","volume":"34","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang J, Wang Y, Yu J, Gao Y, Yang Y, et al. A NIR-II-Emissive Organic Nanomedicine with Biomimetic Engineering for High-Contrast Targeted Bioimaging and Multiple Phototherapies of Pancreatic Tumors. Adv Funct Mater. 2024;34(41):2406483.","journal-title":"Adv Funct Mater"},{"issue":"1","key":"2712_CR115","doi-asserted-by":"publisher","first-page":"2305279","DOI":"10.1002\/advs.202305279","volume":"11","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Yu R, Zhao C, Liang J, Zhang Y, Su H, et al. CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma. Adv Sci. 2024;11(1):2305279.","journal-title":"Adv Sci"},{"key":"2712_CR116","doi-asserted-by":"publisher","first-page":"120467","DOI":"10.1016\/j.biomaterials.2020.120467","volume":"269","author":"P Wu","year":"2021","unstructured":"Wu P, Zhang B, Ocansey DKW, Xu W, Qian H. Extracellular vesicles: A bright star of nanomedicine. Biomaterials. 2021;269:120467.","journal-title":"Biomaterials"},{"key":"2712_CR117","doi-asserted-by":"publisher","first-page":"121306","DOI":"10.1016\/j.biomaterials.2021.121306","volume":"280","author":"W Zhou","year":"2022","unstructured":"Zhou W, Chen X, Zhou Y, Shi S, Liang C, Yu X, et al. Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer. Biomaterials. 2022;280:121306.","journal-title":"Biomaterials"},{"issue":"1","key":"2712_CR118","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ags3.12379","volume":"5","author":"K Ishido","year":"2021","unstructured":"Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018\/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroent Surg. 2021;5(1):7\u201323.","journal-title":"Ann Gastroent Surg"},{"issue":"3","key":"2712_CR119","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrc1566","volume":"5","author":"M Ferrari","year":"2005","unstructured":"Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161\u201371.","journal-title":"Nat Rev Cancer"},{"issue":"25","key":"2712_CR120","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395\u2013406.","journal-title":"N Engl J Med"},{"issue":"11","key":"2712_CR121","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.3390\/curroncol30110694","volume":"30","author":"I Garajov\u00e1","year":"2023","unstructured":"Garajov\u00e1 I, Peroni M, Gelsomino F, Leonardi F. A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists. Curr Oncol. 2023;30(11):9587\u2013601.","journal-title":"Curr Oncol"},{"key":"2712_CR122","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.2147\/IJN.S413496","volume":"18","author":"H Duan","year":"2023","unstructured":"Duan H, Li L, He S. Advances and Prospects in the Treatment of Pancreatic Cancer. Int J Nanomed. 2023;18:3973\u201388.","journal-title":"Int J Nanomed"},{"issue":"1","key":"2712_CR123","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1517\/14796694.1.1.7","volume":"1","author":"L Toschi","year":"2005","unstructured":"Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncol. 2005;1(1):7\u201317.","journal-title":"Future Oncol"},{"issue":"7","key":"2712_CR124","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1021\/acs.jproteome.3c00890","volume":"23","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Ren X, Zhao J, Liu G, Liu F, Guo X, et al. Exploring the Molecular Therapeutic Mechanisms of Gemcitabine through Quantitative Proteomics. J Proteome Res. 2024;23(7):2343\u201354.","journal-title":"J Proteome Res"},{"issue":"2","key":"2712_CR125","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ymthe.2019.11.026","volume":"28","author":"A Frances","year":"2020","unstructured":"Frances A, Cordelier P. The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy? Mol Ther. 2020;28(2):357\u201366.","journal-title":"Mol Ther"},{"issue":"2","key":"2712_CR126","doi-asserted-by":"publisher","first-page":"C540","DOI":"10.1152\/ajpcell.00331.2022","volume":"324","author":"AK Beutel","year":"2022","unstructured":"Beutel AK, Halbrook CJ. Barriers and opportunities for gemcitabine in pancreatic cancer therapy. Am J Physiology-Cell Physiol. 2022;324(2):C540\u201352.","journal-title":"Am J Physiology-Cell Physiol"},{"key":"2712_CR127","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jcis.2023.12.166","volume":"659","author":"M Bartkowski","year":"2024","unstructured":"Bartkowski M, Bincoletto V, Salaroglio IC, Ceccone G, Arenal R, Nervo S, et al. Enhancing pancreatic ductal adenocarcinoma (PDAC) therapy with targeted carbon nano-onion (CNO)-mediated delivery of gemcitabine (GEM)-derived prodrugs. J Colloid Interface Sci. 2024;659:339\u201354.","journal-title":"J Colloid Interface Sci"},{"issue":"3","key":"2712_CR128","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1021\/acsami.9b16209","volume":"12","author":"L Wu","year":"2020","unstructured":"Wu L, Zhang F, Chen X, Wan J, Wang Y, Li T, et al. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma. ACS Appl Mater Interfaces. 2020;12(3):3327\u201340.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"24","key":"2712_CR129","first-page":"28160","volume":"7","author":"Z Li","year":"2024","unstructured":"Li Z, Yang J, Chen B, Kuang Y, Shu R, Xu C, et al. Nanosized Liposomes Loaded with Paclitaxel Palmitate and Gemcitabine Hydrochloride for Anti-Pancreatic Cancer Therapy. ACS Appl Mater Interfaces. 2024;7(24):28160\u201371.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2712_CR130","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jconrel.2022.12.054","volume":"354","author":"S Geng","year":"2023","unstructured":"Geng S, Zhang X, Luo T, Jiang M, Chu C, Wu L, et al. Combined chemotherapy based on bioactive black phosphorus for pancreatic cancer therapy. J Controlled Release. 2023;354:889\u2013901.","journal-title":"J Controlled Release"},{"issue":"6","key":"2712_CR131","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s12274-019-2342-7","volume":"12","author":"K Shi","year":"2019","unstructured":"Shi K, Xue B, Jia Y, Yuan L, Han R, Yang F, et al. Sustained co-delivery of gemcitabine and cis-platinum via biodegradable thermo-sensitive hydrogel for synergistic combination therapy of pancreatic cancer. Nano Res. 2019;12(6):1389\u201399.","journal-title":"Nano Res"},{"issue":"30","key":"2712_CR132","doi-asserted-by":"publisher","first-page":"2214598","DOI":"10.1002\/adfm.202214598","volume":"33","author":"Z Yao","year":"2023","unstructured":"Yao Z, Hu Q, Jin P, Li B, Huang Y, Zhang F, et al. A Self-Assembly Combined Nano-Prodrug to Overcome Gemcitabine Chemo-Resistance of Pancreatic Tumors. Adv Funct Mater. 2023;33(30):2214598.","journal-title":"Adv Funct Mater"},{"key":"2712_CR133","doi-asserted-by":"publisher","first-page":"216138","DOI":"10.1016\/j.canlet.2023.216138","volume":"560","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wu B, Nie G, Wei J, Li Y. Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies. Cancer Lett. 2023;560:216138.","journal-title":"Cancer Lett"},{"issue":"10","key":"2712_CR134","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrclinonc.2010.120","volume":"7","author":"RD Baird","year":"2010","unstructured":"Baird RD, Tan DSP, Kaye SB. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol. 2010;7(10):575\u201382.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2712_CR135","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0378-5173(01)00986-3","volume":"235","author":"AK Singla","year":"2002","unstructured":"Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235(1):179\u201392.","journal-title":"Int J Pharm"},{"key":"2712_CR136","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.canlet.2017.06.026","volume":"403","author":"C Borsoi","year":"2017","unstructured":"Borsoi C, Leonard F, Lee Y, Zaid M, Elganainy D, Alexander JF, et al. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett. 2017;403:296\u2013304.","journal-title":"Cancer Lett"},{"issue":"1","key":"2712_CR137","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pan.2018.10.003","volume":"19","author":"MA Javed","year":"2019","unstructured":"Javed MA, Beyer G, Le N, Vinci A, Wong H, Palmer D, et al. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology. 2019;19(1):97\u2013104.","journal-title":"Pancreatology"},{"issue":"2","key":"2712_CR138","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.pan.2021.12.013","volume":"22","author":"T Emori","year":"2022","unstructured":"Emori T, Itonaga M, Ashida R, Tamura T, Kawaji Y, Hatamaru K, et al. Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gemcitabine and nab-paclitaxel chemotherapy. Pancreatology. 2022;22(2):277\u201385.","journal-title":"Pancreatology"},{"key":"2712_CR139","doi-asserted-by":"publisher","first-page":"101199","DOI":"10.1016\/j.mtbio.2024.101199","volume":"28","author":"NMR Nakka","year":"2024","unstructured":"Nakka NMR, Rachamala HK, Angom RS, Indla NR, Dutta SK, Wang E, et al. Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma. Mater Today Bio. 2024;28:101199.","journal-title":"Mater Today Bio"},{"issue":"21","key":"2712_CR140","doi-asserted-by":"publisher","first-page":"2001115","DOI":"10.1002\/adhm.202001115","volume":"9","author":"SJ Wade","year":"2020","unstructured":"Wade SJ, Sahin Z, Piper A-K, Talebian S, Aghmesheh M, Foroughi J, et al. Dual Delivery of Gemcitabine and Paclitaxel by Wet-Spun Coaxial Fibers Induces Pancreatic Ductal Adenocarcinoma Cell Death, Reduces Tumor Volume, and Sensitizes Cells to Radiation. Adv Healthc Mater. 2020;9(21):2001115.","journal-title":"Adv Healthc Mater"},{"key":"2712_CR141","doi-asserted-by":"crossref","unstructured":"Chauhan SS, Shetty AB, Hatami E, Chowdhury P, Yallapu MM. Pectin-Tannic Acid Nano-Complexes Promote the Delivery and Bioactivity of Drugs in Pancreatic Cancer Cells. Pharmaceutics. 2020;12(3):285.","DOI":"10.3390\/pharmaceutics12030285"},{"key":"2712_CR142","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.colsurfb.2015.08.038","volume":"135","author":"KI David","year":"2015","unstructured":"David KI, Jaidev LR, Sethuraman S, Krishnan UM. Dual drug loaded chitosan nanoparticles\u2014sugar-coated arsenal against pancreatic cancer. Colloids Surf B. 2015;135:689\u201398.","journal-title":"Colloids Surf B"},{"issue":"4","key":"2712_CR143","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.annonc.2019.12.007","volume":"31","author":"ME Salem","year":"2020","unstructured":"Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, et al. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Ann Oncol. 2020;31(4):480\u20136.","journal-title":"Ann Oncol"},{"issue":"4suppl","key":"2712_CR144","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/JCO.2018.36.4_suppl.471","volume":"36","author":"DC Glassman","year":"2018","unstructured":"Glassman DC, Desai AM, Ku GY, Li J, Harding JJ, Varghese AM, et al. Nano-liposomal irinotecan and 5-FU\/LV (N\u2009+\u2009F) for the treatment of advanced PDAC: Memorial Sloan Kettering (MSK) Single Cancer Center Evaluation. J Clin Oncol. 2018;36(4suppl):471.","journal-title":"J Clin Oncol"},{"key":"2712_CR145","doi-asserted-by":"publisher","first-page":"104386","DOI":"10.1016\/j.critrevonc.2024.104386","volume":"201","author":"BS Chen","year":"2024","unstructured":"Chen BS, Chan S-Y, Bteich F, Kuang C, Meyerhardt JA, Ma KS-K. Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic review and meta-analysis. Crit Rev Oncol\/Hemat. 2024;201:104386.","journal-title":"Crit Rev Oncol\/Hemat"},{"key":"2712_CR146","doi-asserted-by":"publisher","first-page":"142690","DOI":"10.1016\/j.cej.2023.142690","volume":"464","author":"Y Li","year":"2023","unstructured":"Li Y, Wang X, Ding B, He C, Zhang C, Li J, et al. Synergistic Apoptosis-Ferroptosis: Oxaliplatin loaded amorphous iron oxide nanoparticles for High-efficiency therapy of orthotopic pancreatic cancer and CA19-9 levels decrease. Chem Eng J. 2023;464:142690.","journal-title":"Chem Eng J"},{"issue":"1","key":"2712_CR147","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","volume":"8","author":"J Lu","year":"2017","unstructured":"Lu J, Liu X, Liao Y-P, Salazar F, Sun B, Jiang W, et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun. 2017;8(1):1811.","journal-title":"Nat Commun"},{"key":"2712_CR148","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jconrel.2015.01.026","volume":"201","author":"C Poon","year":"2015","unstructured":"Poon C, He C, Liu D, Lu K, Lin W. Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer. J Controlled Release. 2015;201:90\u20139.","journal-title":"J Controlled Release"},{"issue":"5","key":"2712_CR149","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/adfm.201401583","volume":"25","author":"F Li","year":"2015","unstructured":"Li F, Zhao X, Wang H, Zhao R, Ji T, Ren H, et al. Multiple Layer-by-Layer Lipid-Polymer Hybrid Nanoparticles for Improved FOLFIRINOX Chemotherapy in Pancreatic Tumor Models. Adv Funct Mater. 2015;25(5):788\u201398.","journal-title":"Adv Funct Mater"},{"issue":"16","key":"2712_CR150","doi-asserted-by":"publisher","first-page":"2100876","DOI":"10.1002\/advs.202100876","volume":"8","author":"X Cheng","year":"2021","unstructured":"Cheng X, Gao J, Ding Y, Lu Y, Wei Q, Cui D, et al. Multi-Functional Liposome: A Powerful Theranostic Nano-Platform Enhancing Photodynamic Therapy. Adv Sci. 2021;8(16):2100876.","journal-title":"Adv Sci"},{"key":"2712_CR151","doi-asserted-by":"publisher","first-page":"121476","DOI":"10.1016\/j.biomaterials.2022.121476","volume":"283","author":"D Li","year":"2022","unstructured":"Li D, Chen X, Wang D, Wu H, Wen H, Wang L, et al. Synchronously boosting type-I photodynamic and photothermal efficacies via molecular manipulation for pancreatic cancer theranostics in the NIR-II window. Biomaterials. 2022;283:121476.","journal-title":"Biomaterials"},{"issue":"5","key":"2712_CR152","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1021\/acsanm.1c04353","volume":"5","author":"SS Hafiz","year":"2022","unstructured":"Hafiz SS, Xavierselvan M, Gokalp S, Labadini D, Barros S, Duong J, et al. Eutectic Gallium\u2013Indium Nanoparticles for Photodynamic Therapy of Pancreatic Cancer. ACS Appl Nano Mate. 2022;5(5):6125\u201339.","journal-title":"ACS Appl Nano Mate"},{"issue":"33","key":"2712_CR153","doi-asserted-by":"publisher","first-page":"18856","DOI":"10.1021\/acsami.5b05724","volume":"7","author":"F Ding","year":"2015","unstructured":"Ding F, Li H-J, Wang J-X, Tao W, Zhu Y-H, Yu Y, et al. Chlorin e6-Encapsulated Polyphosphoester Based Nanocarriers with Viscous Flow Core for Effective Treatment of Pancreatic Cancer. ACS Appl Mater Interfaces. 2015;7(33):18856\u201365.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"8","key":"2712_CR154","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1021\/acs.molpharmaceut.3c00453","volume":"20","author":"DN Dorst","year":"2023","unstructured":"Dorst DN, Smeets EMM, Klein C, Frielink C, Geijs D, Trajkovic-Arsic M, et al. Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma. Mol Pharm. 2023;20(8):4319\u201330.","journal-title":"Mol Pharm"},{"issue":"4","key":"2712_CR155","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ultras.2008.02.003","volume":"48","author":"K Tachibana","year":"2008","unstructured":"Tachibana K, Feril LB, Ikeda-Dantsuji Y. Sonodynamic therapy. Ultrasonics. 2008;48(4):253\u20139.","journal-title":"Ultrasonics"},{"key":"2712_CR156","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.actbio.2021.05.029","volume":"129","author":"J Cao","year":"2021","unstructured":"Cao J, Sun Y, Zhang C, Wang X, Zeng Y, Zhang T, et al. Tablet-like TiO2\/C nanocomposites for repeated type I sonodynamic therapy of pancreatic cancer. Acta Biomater. 2021;129:269\u201379.","journal-title":"Acta Biomater"},{"issue":"12","key":"2712_CR157","doi-asserted-by":"publisher","first-page":"12849","DOI":"10.1021\/acsnano.7b08225","volume":"11","author":"J Chen","year":"2017","unstructured":"Chen J, Luo H, Liu Y, Zhang W, Li H, Luo T, et al. Oxygen-Self-Produced Nanoplatform for Relieving Hypoxia and Breaking Resistance to Sonodynamic Treatment of Pancreatic Cancer. ACS Nano. 2017;11(12):12849\u201362.","journal-title":"ACS Nano"},{"issue":"1","key":"2712_CR158","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","volume":"13","author":"Y Qian","year":"2020","unstructured":"Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020;13(1):130.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2712_CR159","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1002\/mco2.181","volume":"3","author":"G-H Liu","year":"2022","unstructured":"Liu G-H, Chen T, Zhang X, Ma X-L, Shi H-S. Small molecule inhibitors targeting the cancers. MedComm. 2022;3(4):e181.","journal-title":"MedComm"},{"issue":"1","key":"2712_CR160","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1101\/gad.1753809","volume":"23","author":"O Nolan-Stevaux","year":"2009","unstructured":"Nolan-Stevaux O, Lau J, Truitt ML, Chu GC, Hebrok M, Fern\u00e1ndez-Zapico ME, et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009;23(1):24\u201336.","journal-title":"Genes Dev"},{"issue":"6","key":"2712_CR161","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1039\/C4NR06300G","volume":"7","author":"N Zhang","year":"2015","unstructured":"Zhang N, Liu S, Wang N, Deng S, Song L, Wu Q, et al. Biodegradable polymeric micelles encapsulated JK184 suppress tumor growth through inhibiting Hedgehog signaling pathway. Nanoscale. 2015;7(6):2609\u201324.","journal-title":"Nanoscale"},{"issue":"8","key":"2712_CR162","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.nano.2015.07.001","volume":"11","author":"RK Verma","year":"2015","unstructured":"Verma RK, Yu W, Singh SP, Shankar S, Srivastava RK. Anthothecol-encapsulated PLGA nanoparticles inhibit pancreatic cancer stem cell growth by modulating sonic hedgehog pathway. Nanomed Nanotechnol. 2015;11(8):2061\u201370.","journal-title":"Nanomed Nanotechnol"},{"issue":"5933","key":"2712_CR163","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1126\/science.1171362","volume":"324","author":"KP Olive","year":"2009","unstructured":"Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457\u201361.","journal-title":"Science"},{"key":"2712_CR164","doi-asserted-by":"crossref","unstructured":"Lee JJ, Perera RM, Wang H, Wu D-C, Liu XS, Han S et al. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proceedings of the National Academy of Sciences. 2014;111(30):E3091-E100.","DOI":"10.1073\/pnas.1411679111"},{"issue":"7","key":"2712_CR165","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1158\/1078-0432.CCR-20-3715","volume":"27","author":"NG Steele","year":"2021","unstructured":"Steele NG, Biffi G, Kemp SB, Zhang Y, Drouillard D, Syu L, et al. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Clin Cancer Res. 2021;27(7):2023\u201337.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2712_CR166","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-23-0131","volume":"30","author":"T Roy Chaudhuri","year":"2024","unstructured":"Roy Chaudhuri T, Lin Q, Stachowiak EK, Rosario SR, Spernyak JA, Ma WW, et al. Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors. Clin Cancer Res. 2024;30(7):1367\u201381.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2712_CR167","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.xphs.2023.10.019","volume":"113","author":"J Wang","year":"2024","unstructured":"Wang J, Chen T, Ruszaj DM, Mager DE, Straubinger RM. Integrated PK\/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models. J Pharm Sci. 2024;113(1):72\u201384.","journal-title":"J Pharm Sci"},{"issue":"19","key":"2712_CR168","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.3390\/cancers13194869","volume":"13","author":"EN Pijnappel","year":"2021","unstructured":"Pijnappel EN, Wassenaar NPM, Gurney-Champion OJ, Klaassen R, van der Lee K, Pleunis-van Empel MCH, et al. Phase I\/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer. Cancers. 2021;13(19):4869.","journal-title":"Cancers"},{"issue":"2","key":"2712_CR169","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.canlet.2015.09.007","volume":"369","author":"A Bhaw-Luximon","year":"2015","unstructured":"Bhaw-Luximon A, Jhurry D. New avenues for improving pancreatic ductal adenocarcinoma (PDAC) treatment: Selective stroma depletion combined with nano drug delivery. Cance Lett. 2015;369(2):266\u201373.","journal-title":"Cance Lett"},{"key":"2712_CR170","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pharmthera.2016.09.003","volume":"168","author":"KM Mann","year":"2016","unstructured":"Mann KM, Ying H, Juan J, Jenkins NA, Copeland NG. KRAS-related proteins in pancreatic cancer. Pharmacol Ther. 2016;168:29\u201342.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2712_CR171","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/s41467-017-00942-5","volume":"8","author":"MD Muzumdar","year":"2017","unstructured":"Muzumdar MD, Chen P-Y, Dorans KJ, Chung KM, Bhutkar A, Hong E, et al. Survival of pancreatic cancer cells lacking KRAS function. Nat Commun. 2017;8(1):1090.","journal-title":"Nat Commun"},{"issue":"1","key":"2712_CR172","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu ZI, O\u2019Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21(1):7\u201324.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"45","key":"2712_CR173","doi-asserted-by":"publisher","first-page":"61583","DOI":"10.1021\/acsami.4c10404","volume":"16","author":"Q Hu","year":"2024","unstructured":"Hu Q, Feng J, Qi L, Jin Y. Stromal Reprogramming Optimizes KRAS-Specific Chemotherapy Inducing Antitumor Immunity in Pancreatic Cancer. ACS Appl Mater Interfaces. 2024;16(45):61583\u201398.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2712_CR174","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jconrel.2024.07.032","volume":"373","author":"AM L\u00f3pez-Est\u00e9vez","year":"2024","unstructured":"L\u00f3pez-Est\u00e9vez AM, Sanjurjo L, Turrero \u00c1, Arriaga I, Abrescia NGA, Poveda A, et al. Nanotechnology-assisted intracellular delivery of antibody as a precision therapy approach for KRAS-driven tumors. J Controlled Release. 2024;373:277\u201392.","journal-title":"J Controlled Release"},{"issue":"3","key":"2712_CR175","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ymthe.2025.01.023","volume":"33","author":"X Liu","year":"2025","unstructured":"Liu X, Yang J, Huang S, Hong Y, Zhu Y, Wang J, et al. Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRASG12D protein to cancer-associated fibroblasts. Mol Ther. 2025;33(3):1134\u201353.","journal-title":"Mol Ther"},{"issue":"1","key":"2712_CR176","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2159-8290.CD-24-0489","volume":"15","author":"Y Liu","year":"2025","unstructured":"Liu Y, Han J, Hsu W-H, LaBella KA, Deng P, Shang X, et al. Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. Cancer Discov. 2025;15(1):162\u201378.","journal-title":"Cancer Discov"},{"issue":"1","key":"2712_CR177","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"H Strickler John","year":"2023","unstructured":"Strickler John H, Satake H, George Thomas J, Yaeger R, Hollebecque A, Garrido-Laguna I, et al. Sotorasib in KRAS p.G12C\u2013Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023;388(1):33\u201343.","journal-title":"N Engl J Med"},{"key":"2712_CR178","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.addr.2018.06.014","volume":"130","author":"H Meng","year":"2018","unstructured":"Meng H, Nel AE. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer. Adv Drug Delivery Rev. 2018;130:50\u20137.","journal-title":"Adv Drug Delivery Rev"},{"key":"2712_CR179","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jconrel.2020.06.001","volume":"324","author":"D Chen","year":"2020","unstructured":"Chen D, Zhu X, Tao W, Kong Y, Huag Y, Zhang Y, et al. Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. J Controlled Release. 2020;324:545\u201359.","journal-title":"J Controlled Release"},{"issue":"9","key":"2712_CR180","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","volume":"15","author":"A Ashworth","year":"2018","unstructured":"Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors? Nat Rev Clin Oncol. 2018;15(9):564\u201376.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2712_CR181","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balma\u00f1a J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J clin oncol. 2015;33(3):244\u201350.","journal-title":"J clin oncol"},{"issue":"5","key":"2712_CR182","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","volume":"7","author":"M Javle","year":"2021","unstructured":"Javle M, Shacham-Shmueli E, Xiao L, Varadhachary G, Halpern N, Fogelman D, et al. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. JAMA Oncol. 2021;7(5):693\u20139.","journal-title":"JAMA Oncol"},{"issue":"13","key":"2712_CR183","doi-asserted-by":"publisher","first-page":"12915","DOI":"10.1021\/acsnano.3c05009","volume":"17","author":"X Long","year":"2023","unstructured":"Long X, Dai A, Huang T, Niu W, Liu L, Xu H, et al. Simultaneous Delivery of Dual Inhibitors of DNA Damage Repair Sensitizes Pancreatic Cancer Response to Irreversible Electroporation. ACS Nano. 2023;17(13):12915\u201332.","journal-title":"ACS Nano"},{"key":"2712_CR184","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3389\/fimmu.2021.762989","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zheng K, Xiong H, Huang Y, Chen X, Zhou Y, et al. PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer. Front Immunol. 2021;12:2021.","journal-title":"Front Immunol"},{"issue":"5","key":"2712_CR185","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1706910","volume":"381","author":"KA High","year":"2019","unstructured":"High KA, Roncarolo MG. Gene Therapy. N Engl J Med. 2019;381(5):455\u201364.","journal-title":"N Engl J Med"},{"issue":"11","key":"2712_CR186","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1997","volume":"6","author":"GA Calin","year":"2006","unstructured":"Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857\u201366.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"2712_CR187","doi-asserted-by":"publisher","first-page":"e3100","DOI":"10.1038\/cddis.2017.495","volume":"8","author":"E Slab\u00e1kov\u00e1","year":"2017","unstructured":"Slab\u00e1kov\u00e1 E, Culig Z, Rem\u0161\u00edk J, Sou\u010dek K. Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis. 2017;8(10):e3100\u2013e.","journal-title":"Cell Death Dis"},{"issue":"7","key":"2712_CR188","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-17-2733","volume":"24","author":"M-E Gilles","year":"2018","unstructured":"Gilles M-E, Hao L, Huang L, Rupaimoole R, Lopez-Casas PP, Pulver E, et al. Personalized RNA Medicine for Pancreatic Cancer. Clin Cancer Res. 2018;24(7):1734\u201347.","journal-title":"Clin Cancer Res"},{"key":"2712_CR189","doi-asserted-by":"crossref","unstructured":"Papadakos SP, Dedes N, Pergaris A, Gazouli M, Theocharis S. Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment? Int J Mol Sci. 2022;23(7):3620.","DOI":"10.3390\/ijms23073620"},{"issue":"18","key":"2712_CR190","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1158\/0008-5472.CAN-18-0124","volume":"78","author":"Y Binenbaum","year":"2018","unstructured":"Binenbaum Y, Fridman E, Yaari Z, Milman N, Schroeder A, Ben David G, et al. Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma. Cancer Res. 2018;78(18):5287\u201399.","journal-title":"Cancer Res"},{"issue":"10","key":"2712_CR191","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1039\/C4TB01623H","volume":"3","author":"C Yang","year":"2015","unstructured":"Yang C, Hu R, Anderson T, Wang Y, Lin G, Law W-C, et al. Biodegradable nanoparticle-mediated K-ras down regulation for pancreatic cancer gene therapy. J Mater Chem B. 2015;3(10):2163\u201372.","journal-title":"J Mater Chem B"},{"key":"2712_CR192","doi-asserted-by":"publisher","first-page":"149884","DOI":"10.1016\/j.cej.2024.149884","volume":"485","author":"L Cao","year":"2024","unstructured":"Cao L, Dong M, Jiang K, Zhu Q, Li F, Xiao Z, et al. Triblock polymer PDMAEMA-co-PNIPAM-co-PMPC to deliver siKRAS for gene therapy in pancreatic cancer. Chem Eng J. 2024;485:149884.","journal-title":"Chem Eng J"},{"key":"2712_CR193","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2023.03.016","volume":"357","author":"S Anthiya","year":"2023","unstructured":"Anthiya S, \u00d6zt\u00fcrk SC, Yanik H, Tavukcuoglu E, \u015eahin A, Datta D, et al. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors. J Controlled Release. 2023;357:67\u201383.","journal-title":"J Controlled Release"},{"issue":"7659","key":"2712_CR194","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546(7659):498\u2013503.","journal-title":"Nature"},{"key":"2712_CR195","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.actbio.2023.07.008","volume":"168","author":"R Huang","year":"2023","unstructured":"Huang R, Du H, Cheng L, Zhang P, Meng F, Zhong Z. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer. Acta Biomater. 2023;168:529\u201339.","journal-title":"Acta Biomater"},{"issue":"2","key":"2712_CR196","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.molcel.2021.12.002","volume":"82","author":"G Liu","year":"2022","unstructured":"Liu G, Lin Q, Jin S, Gao C. The CRISPR-Cas toolbox and gene editing technologies. Mol Cell. 2022;82(2):333\u201347.","journal-title":"Mol Cell"},{"issue":"5","key":"2712_CR197","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/d41573-023-00050-8","volume":"22","author":"K Kingwell","year":"2023","unstructured":"Kingwell K. First CRISPR therapy seeks landmark approval. Nat Rev Drug Discov. 2023;22(5):339\u201341.","journal-title":"Nat Rev Drug Discov"},{"key":"2712_CR198","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jconrel.2019.05.019","volume":"304","author":"M Li","year":"2019","unstructured":"Li M, Xie H, Liu Y, Xia C, Cun X, Long Y, et al. Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR\/Cas9 system suppressed the metastasis of pancreatic cancer. J Controlled Release. 2019;304:204\u201315.","journal-title":"J Controlled Release"},{"key":"2712_CR199","doi-asserted-by":"crossref","unstructured":"Kathleen MM, Fei X, Antonios C, Valerie SL, Fernanda GK, Raghu K. Exosome-mediated delivery of CRISPR\/Cas9 for targeting of oncogenic KrasG12Din pancreatic cancer. Life Sci Alliance. 2021;4(9):e202000875.","DOI":"10.26508\/lsa.202000875"},{"key":"2712_CR200","doi-asserted-by":"publisher","first-page":"123456","DOI":"10.1016\/j.biomaterials.2025.123456","volume":"324","author":"VJ Kast","year":"2026","unstructured":"Kast VJ, Hauser S, Nadernezhad A, Pette D, Maitz MF, Petzold A, et al. A biomaterial-based platform of pancreatic cancer reveals kallikrein-related peptidase 6 (KLK6) as a mediator of neutrophil recruitment and immunosuppression. Biomaterials. 2026;324:123456.","journal-title":"Biomaterials"},{"issue":"45","key":"2712_CR201","doi-asserted-by":"publisher","first-page":"28068","DOI":"10.1073\/pnas.2009899117","volume":"117","author":"X Wei","year":"2020","unstructured":"Wei X, Yang J, Adair SJ, Ozturk H, Kuscu C, Lee KY, et al. Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. Proc Natl Acad Scis. 2020;117(45):28068\u201379.","journal-title":"Proc Natl Acad Scis"},{"issue":"21","key":"2712_CR202","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1158\/1078-0432.CCR-21-3452","volume":"28","author":"B Bockorny","year":"2022","unstructured":"Bockorny B, Grossman JE, Hidalgo M. Facts and Hopes in Immunotherapy of Pancreatic Cancer. Clin Cancer Res. 2022;28(21):4606\u201317.","journal-title":"Clin Cancer Res"},{"key":"2712_CR203","doi-asserted-by":"crossref","unstructured":"Di Federico A, Mosca M, Pagani R, Carloni R, Frega G, De Giglio A et al. Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers. 2022;14(10):2429.","DOI":"10.3390\/cancers14102429"},{"issue":"1","key":"2712_CR204","first-page":"53","volume":"9","author":"X Huang","year":"2022","unstructured":"Huang X, Zhang G, Tang T-Y, Gao X, Liang T-B. Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine. Mil Med Res. 2022;9(1):53.","journal-title":"Mil Med Res"},{"issue":"34","key":"2712_CR205","doi-asserted-by":"publisher","first-page":"e04886","DOI":"10.1002\/advs.202504886","volume":"12","author":"L Luo","year":"2025","unstructured":"Luo L, Wang X, Liao Y-P, Nel AE. KRAS mRNA Spleen-Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer. Adv Sci. 2025;12(34):e04886.","journal-title":"Adv Sci"},{"issue":"9","key":"2712_CR206","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1021\/acsnano.4c14102","volume":"19","author":"X Xu","year":"2025","unstructured":"Xu X, Wang X, Liao Y-P, Luo L, Nel AE. Reprogramming the Tolerogenic Immune Response Against Pancreatic Cancer Metastases by Lipid Nanoparticles Delivering a STING Agonist Plus Mutant KRAS mRNA. ACS Nano. 2025;19(9):8579\u201394.","journal-title":"ACS Nano"},{"key":"2712_CR207","doi-asserted-by":"publisher","first-page":"113588","DOI":"10.1016\/j.jconrel.2025.113588","volume":"381","author":"Q Shen","year":"2025","unstructured":"Shen Q, Liu J, Zeng L, Ren Y, Liao J, Chen S, et al. Pancreas-targeted lipid nanoparticles for relatively non-invasive interleukin-12 mRNA therapy in orthotopic pancreatic ductal adenocarcinoma. J Controlled Release. 2025;381:113588.","journal-title":"J Controlled Release"},{"issue":"11","key":"2712_CR208","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"J-F Bosset","year":"2006","unstructured":"Bosset J-F, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with Preoperative Radiotherapy in Rectal Cancer. N Eng J Med. 2006;355(11):1114\u201323.","journal-title":"N Eng J Med"},{"issue":"15","key":"2712_CR209","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1039\/D0BM00623H","volume":"8","author":"X Liu","year":"2020","unstructured":"Liu X, Zhang M, Yan D, Deng G, Wang Q, Li C, et al. A smart theranostic agent based on Fe-HPPy@Au\/DOX for CT imaging and PTT\/chemotherapy\/CDT combined anticancer therapy. Biomater Sci. 2020;8(15):4067\u201372.","journal-title":"Biomater Sci"},{"issue":"1","key":"2712_CR210","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13014-023-02328-y","volume":"18","author":"IS Jan","year":"2023","unstructured":"Jan IS, Ch\u2019ang HJ. Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy. Radiat Oncol. 2023;18(1):137.","journal-title":"Radiat Oncol"},{"issue":"3","key":"2712_CR211","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1166\/jbn.2020.2898","volume":"16","author":"W Dong","year":"2020","unstructured":"Dong W, Cai Z, Pang J, Wang J, Tang N, Zhang W, et al. Radiotherapy Enhancement for Human Pancreatic Carcinoma Using a Peptide-Gold Nanoparticle Hybrid. J Biomed Nanotechnol. 2020;16(3):352\u201363.","journal-title":"J Biomed Nanotechnol"},{"issue":"5","key":"2712_CR212","doi-asserted-by":"publisher","first-page":"9084","DOI":"10.1021\/acsnano.1c02283","volume":"15","author":"D Manoharan","year":"2021","unstructured":"Manoharan D, Chang L-C, Wang L-C, Shan Y-S, Lin F-C, Wu L-C, et al. Synchronization of Nanoparticle Sensitization and Radiosensitizing Chemotherapy through Cell Cycle Arrest Achieving Ultralow X-ray Dose Delivery to Pancreatic Tumors. ACS Nano. 2021;15(5):9084\u2013100.","journal-title":"ACS Nano"},{"key":"2712_CR213","doi-asserted-by":"publisher","first-page":"122710","DOI":"10.1016\/j.biomaterials.2024.122710","volume":"311","author":"J Wang","year":"2024","unstructured":"Wang J, Wu C, Wang Y, Shen Y, Wu K, Shi Y, et al. Nano-enabled regulation of DNA damage in tumor cells to enhance neoantigen-based pancreatic cancer immunotherapy. Biomaterials. 2024;311:122710.","journal-title":"Biomaterials"},{"issue":"9","key":"2712_CR214","doi-asserted-by":"publisher","first-page":"8377","DOI":"10.1007\/s12274-024-6860-6","volume":"17","author":"J Hong","year":"2024","unstructured":"Hong J, Xian S, Zheng S, Wang H, Jiang D. Addressing chemoresistance with a lipid gemcitabine nanotherapeutic strategy for effective treatment of pancreatic cancer. Nano Res. 2024;17(9):8377\u201388.","journal-title":"Nano Res"},{"key":"2712_CR215","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biomaterials.2017.12.015","volume":"158","author":"X Zhao","year":"2018","unstructured":"Zhao X, Wang X, Sun W, Cheng K, Qin H, Han X, et al. Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. Biomaterials. 2018;158:44\u201355.","journal-title":"Biomaterials"},{"key":"2712_CR216","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jconrel.2024.01.055","volume":"367","author":"J Yan","year":"2024","unstructured":"Yan J, Wang M, Lv S, Chen D, Wu Z, Zhou D, et al. SiATG5-loaded cancer cell membrane-fused liposomes induced increased uptake of albumin-bound chemotherapeutics by pancreatic cancer cells. J Controlled Release. 2024;367:620\u201336.","journal-title":"J Controlled Release"},{"issue":"38","key":"2712_CR217","doi-asserted-by":"publisher","first-page":"e07118","DOI":"10.1002\/advs.202507118","volume":"12","author":"H Fan","year":"2025","unstructured":"Fan H, Chen H, Song H, Li C, Wang Y, Zhao Z, et al. Cascade-Targeted Nanoparticles for Enhanced Gemcitabine Delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer. Adv Sci. 2025;12(38):e07118.","journal-title":"Adv Sci"},{"issue":"14","key":"2712_CR218","doi-asserted-by":"publisher","first-page":"13611","DOI":"10.1021\/acsnano.3c02272","volume":"17","author":"S Yuan","year":"2023","unstructured":"Yuan S, Mu W, Liu S, Liu M, Xia Z, Liang S, et al. Transforming Cancer-Associated Fibroblast Barrier into Drug Depots to Boost Chemo-Immunotherapy in Shooting Fish in a Barrel Pattern. ACS Nano. 2023;17(14):13611\u201326.","journal-title":"ACS Nano"},{"key":"2712_CR219","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jconrel.2023.07.061","volume":"361","author":"X Zhou","year":"2023","unstructured":"Zhou X, Zhang P, Liu N, Zhang X, Lv H, Xu W, et al. Enhancing chemotherapy for pancreatic cancer through efficient and sustained tumor microenvironment remodeling with a fibroblast-targeted nanosystem. J Controlled Release. 2023;361:161\u201377.","journal-title":"J Controlled Release"},{"issue":"10","key":"2712_CR220","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1021\/jacs.0c00650","volume":"142","author":"H Han","year":"2020","unstructured":"Han H, Hou Y, Chen X, Zhang P, Kang M, Jin Q, et al. Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy. J Am Chem Soc. 2020;142(10):4944\u201354.","journal-title":"J Am Chem Soc"},{"issue":"20","key":"2712_CR221","doi-asserted-by":"publisher","first-page":"5348","DOI":"10.1158\/1078-0432.CCR-20-0489","volume":"26","author":"E Dotan","year":"2020","unstructured":"Dotan E, Cardin DB, Lenz H-J, Messersmith W, O\u2019Neil B, Cohen SJ, et al. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Clin Cancer Res. 2020;26(20):5348\u201357.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2712_CR222","doi-asserted-by":"publisher","first-page":"8692","DOI":"10.7150\/thno.60437","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Tao Y, He M, Deng M, Guo R, Sheng Q, et al. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis. Theranostics. 2021;11(18):8692\u2013705.","journal-title":"Theranostics"},{"issue":"9","key":"2712_CR223","doi-asserted-by":"publisher","first-page":"14149","DOI":"10.1021\/acsnano.0c08860","volume":"15","author":"X Zhao","year":"2021","unstructured":"Zhao X, Yang X, Wang X, Zhao X, Zhang Y, Liu S, et al. Penetration Cascade of Size Switchable Nanosystem in Desmoplastic Stroma for Improved Pancreatic Cancer Therapy. ACS Nano. 2021;15(9):14149\u201361.","journal-title":"ACS Nano"},{"issue":"21","key":"2712_CR224","doi-asserted-by":"publisher","first-page":"8744","DOI":"10.1021\/acs.nanolett.2c03663","volume":"22","author":"N Yu","year":"2022","unstructured":"Yu N, Zhang X, Zhong H, Mu J, Li X, Liu T, et al. Stromal Homeostasis-Restoring Nanomedicine Enhances Pancreatic Cancer Chemotherapy. Nano Lett. 2022;22(21):8744\u201354.","journal-title":"Nano Lett"},{"key":"2712_CR225","doi-asserted-by":"publisher","first-page":"101533","DOI":"10.1016\/j.nantod.2022.101533","volume":"45","author":"D Wei","year":"2022","unstructured":"Wei D, Cheng X, Du C, Wang Y, Sun J, Li C, et al. Stroma-targeted nanoparticles that remodel stromal alignment to enhance drug delivery and improve the antitumor efficacy of Nab-paclitaxel in pancreatic ductal adenocarcinoma models. Nano Today. 2022;45:101533.","journal-title":"Nano Today"},{"key":"2712_CR226","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.biomaterials.2019.04.005","volume":"208","author":"S Khan","year":"2019","unstructured":"Khan S, Setua S, Kumari S, Dan N, Massey A, Hafeez BB, et al. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Biomaterials. 2019;208:83\u201397.","journal-title":"Biomaterials"},{"issue":"1","key":"2712_CR227","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12274-019-2610-6","volume":"13","author":"T Zhang","year":"2020","unstructured":"Zhang T, Jiang Z, Chen L, Pan C, Sun S, Liu C, et al. PCN-Fe(III)-PTX nanoparticles for MRI guided high efficiency chemo-photodynamic therapy in pancreatic cancer through alleviating tumor hypoxia. Nano Res. 2020;13(1):273\u201381.","journal-title":"Nano Res"},{"issue":"4","key":"2712_CR228","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1021\/acsnano.0c02197","volume":"14","author":"X Chen","year":"2020","unstructured":"Chen X, Gao H, Deng Y, Jin Q, Ji J, Ding D. Supramolecular Aggregation-Induced Emission Nanodots with Programmed Tumor Microenvironment Responsiveness for Image-Guided Orthotopic Pancreatic Cancer Therapy. ACS Nano. 2020;14(4):5121\u201334.","journal-title":"ACS Nano"},{"issue":"17","key":"2712_CR229","doi-asserted-by":"publisher","first-page":"2412707","DOI":"10.1002\/smll.202412707","volume":"21","author":"M Li","year":"2025","unstructured":"Li M, Li T, Liu Y, Han D, Wu S, Gong J. Dual Cascade-Responsive Multifunctional Nanoparticles to Overcome Bacterium-Induced Drug Inactivation and Enhanced Photodynamic and Chemo-Immunotherapy of Pancreatic Cancer. Small. 2025;21(17):2412707.","journal-title":"Small"},{"issue":"5","key":"2712_CR230","doi-asserted-by":"publisher","first-page":"1805936","DOI":"10.1002\/adma.201805936","volume":"31","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhang Y, Xue Y, Wu Y, Wang Q, Xue L, et al. Transforming Weakness into Strength: Photothermal-Therapy-Induced Inflammation Enhanced Cytopharmaceutical Chemotherapy as a Combination Anticancer Treatment. Adv Mater. 2019;31(5):1805936.","journal-title":"Adv Mater"},{"key":"2712_CR231","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jconrel.2023.01.007","volume":"354","author":"F Zhang","year":"2023","unstructured":"Zhang F, Hu Q, Li B, Huang Y, Wang M, Shao S, et al. A biomimetic nanodrug for enhanced chemotherapy of pancreatic tumors. J Controlled Release. 2023;354:835\u201350.","journal-title":"J Controlled Release"},{"issue":"1","key":"2712_CR232","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/s12951-022-01738-6","volume":"20","author":"X-Y Yang","year":"2022","unstructured":"Yang X, Zhang J, Zhou Q, Yu J, Lu Y, Wang X, et al. Extracellular matrix modulating enzyme functionalized biomimetic Au nanoplatform-mediated enhanced tumor penetration and synergistic antitumor therapy for pancreatic cancer. J Nanobiotechnol. 2022;20(1):524.","journal-title":"J Nanobiotechnol"},{"issue":"13","key":"2712_CR233","doi-asserted-by":"publisher","first-page":"16539","DOI":"10.1021\/acsami.3c01967","volume":"15","author":"L Liu","year":"2023","unstructured":"Liu L, Xiao X, Guo J, Wang J, Liu S, Wang M, et al. Aptamer and Peptide-Engineered Polydopamine Nanospheres for Target Delivery and Tumor Perfusion in Synergistic Chemo-Phototherapy of Pancreatic Cancer. ACS Appl Mater Interfaces. 2023;15(13):16539\u201351.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2712_CR234","doi-asserted-by":"publisher","first-page":"136124","DOI":"10.1016\/j.cej.2022.136124","volume":"442","author":"S Abudukelimu","year":"2022","unstructured":"Abudukelimu S, Wei G, Huang J, Zhao G, Wei L, Cui W, et al. Polyhedral oligomeric silsesquioxane (POSS)-based hybrid nanocomposite for synergistic chemo-photothermal therapy against pancreatic cancer. Chem Eng J. 2022;442:136124.","journal-title":"Chem Eng J"},{"issue":"42","key":"2712_CR235","doi-asserted-by":"publisher","first-page":"15735","DOI":"10.1039\/D2NR04235E","volume":"14","author":"Q Hu","year":"2022","unstructured":"Hu Q, Xu M, Feng J, Xie H, Li J, He Y, et al. Hyperthermia-induced stellate cell deactivation to enhance dual chemo and pH-responsive photothermal therapy for pancreatic cancers. Nanoscale. 2022;14(42):15735\u201348.","journal-title":"Nanoscale"},{"key":"2712_CR236","doi-asserted-by":"publisher","first-page":"101832","DOI":"10.1016\/j.nantod.2023.101832","volume":"50","author":"W Zhang","year":"2023","unstructured":"Zhang W, Li S, Liu Y, Xing R, Jin Z, Yan X, et al. Immunosuppressive microenvironment improvement and treatment of aggressive malignancy pancreatic ductal adenocarcinoma based on local administration of injectable hydrogel. Nano Today. 2023;50:101832.","journal-title":"Nano Today"},{"key":"2712_CR237","doi-asserted-by":"crossref","unstructured":"Karimnia V, Slack FJ, Celli JP. Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma. Cancers. 2021;13(17):4354.","DOI":"10.3390\/cancers13174354"},{"key":"2712_CR238","doi-asserted-by":"crossref","unstructured":"Yang X, Lu Y, Xu J, Du Y, Yu R. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma. Molecules. 2023;28(3):1506.","DOI":"10.3390\/molecules28031506"},{"key":"2712_CR239","doi-asserted-by":"crossref","unstructured":"Farren MR, Sayegh L, Ware MB, Chen HR, Gong J, Liang Y et al. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. JCI insight. 2020;5(1):e130362.","DOI":"10.1172\/jci.insight.130362"},{"issue":"7","key":"2712_CR240","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","volume":"16","author":"EB Golden","year":"2015","unstructured":"Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795\u2013803.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2712_CR241","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","volume":"2","author":"AR Parikh","year":"2021","unstructured":"Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021;2(11):1124\u201335.","journal-title":"Nat Cancer"},{"issue":"13","key":"2712_CR242","doi-asserted-by":"publisher","first-page":"2419418","DOI":"10.1002\/adma.202419418","volume":"37","author":"S Deng","year":"2025","unstructured":"Deng S, Hu L, Chen G, Ye J, Xiao Z, Guan T, et al. A PD-L1 siRNA-Loaded Boron Nanoparticle for Targeted Cancer Radiotherapy and Immunotherapy. Adv Mater. 2025;37(13):2419418.","journal-title":"Adv Mater"},{"issue":"1","key":"2712_CR243","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1089\/pancan.2021.0003","volume":"7","author":"JJ Hue","year":"2021","unstructured":"Hue JJ, Bingmer K, Sugumar K, Markt SC, Rothermel LD, Hardacre JM, et al. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. J Pancreat Cancer. 2021;7(1):31\u20138.","journal-title":"J Pancreat Cancer"},{"key":"2712_CR244","doi-asserted-by":"crossref","unstructured":"Wang-Gillam A, O\u2019Reilly EM, Bendell JC, Wainberg ZA, Borazanci EH, Bahary N et al. A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) \u00b1 chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2019;37(4_suppl):TPS465\u2013TPS.","DOI":"10.1200\/JCO.2019.37.4_suppl.TPS465"},{"issue":"7963","key":"2712_CR245","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144\u201350.","journal-title":"Nature"},{"issue":"6","key":"2712_CR246","doi-asserted-by":"publisher","first-page":"2002147","DOI":"10.1002\/advs.202002147","volume":"8","author":"X Liu","year":"2021","unstructured":"Liu X, Jiang J, Liao Y-P, Tang I, Zheng E, Qiu W, et al. Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. Adv Sci. 2021;8(6):2002147.","journal-title":"Adv Sci"},{"issue":"8","key":"2712_CR247","doi-asserted-by":"publisher","first-page":"13168","DOI":"10.1021\/acsnano.2c06300","volume":"16","author":"L Luo","year":"2022","unstructured":"Luo L, Wang X, Liao Y-P, Chang CH, Nel AE. Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy. ACS Nano. 2022;16(8):13168\u201382.","journal-title":"ACS Nano"},{"issue":"11","key":"2712_CR248","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1021\/acs.nanolett.4c00002","volume":"24","author":"X Yang","year":"2024","unstructured":"Yang X, Li C, Yang H, Li T, Ling S, Zhang Y, et al. Programmed Remodeling of the Tumor Milieu to Enhance NK Cell Immunotherapy Combined with Chemotherapy for Pancreatic Cancer. Nano Lett. 2024;24(11):3421\u201331.","journal-title":"Nano Lett"},{"issue":"1","key":"2712_CR249","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12951-024-02467-8","volume":"22","author":"M Huai","year":"2024","unstructured":"Huai M, Wang Y, Li J, Pan J, Sun F, Zhang F, et al. Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification. J Nanobiotechnol. 2024;22(1):257.","journal-title":"J Nanobiotechnol"},{"key":"2712_CR250","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jconrel.2025.02.021","volume":"380","author":"J Li","year":"2025","unstructured":"Li J, Dai Y, Wang T, Zhang X, Du P, Dong Y, et al. Polyphenol-based pH-responsive nanoparticles enhance chemo-immunotherapy in pancreatic cancer. J Controlled Release. 2025;380:615\u201329.","journal-title":"J Controlled Release"},{"key":"2712_CR251","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jconrel.2023.07.014","volume":"360","author":"H Zhang","year":"2023","unstructured":"Zhang H, Wang Y, Zhu L, Qi Z, Cao K, Chang J, et al. A bulldozer driven by anoxic bacteria for pancreatic cancer chemo-immunotherapy. J Controlled Release. 2023;360:660\u201371.","journal-title":"J Controlled Release"},{"issue":"29","key":"2712_CR252","doi-asserted-by":"publisher","first-page":"2101208","DOI":"10.1002\/smll.202101208","volume":"17","author":"Q-S Tong","year":"2021","unstructured":"Tong Q, Miao W, Huang H, Luo J, Liu R, Huang Y, et al. A Tumor-Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer. Small. 2021;17(29):2101208.","journal-title":"Small"},{"key":"2712_CR253","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.mattod.2022.11.008","volume":"62","author":"Z Wan","year":"2023","unstructured":"Wan Z, Huang H, West Iii RE, Zhang M, Zhang B, Cai X, et al. Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier. Mater Today. 2023;62:33\u201350.","journal-title":"Mater Today"},{"issue":"10","key":"2712_CR254","doi-asserted-by":"publisher","first-page":"9830","DOI":"10.1021\/acsnano.8b00967","volume":"12","author":"L Shen","year":"2018","unstructured":"Shen L, Li J, Liu Q, Song W, Zhang X, Tiruthani K, et al. Local blockade of interleukin 10 and C-X-C motif chemokine ligand 12 with nano-delivery promotes antitumor response in murine cancers. ACS Nano. 2018;12(10):9830\u201341.","journal-title":"ACS Nano"},{"issue":"11","key":"2712_CR255","doi-asserted-by":"publisher","first-page":"e2418306122","DOI":"10.1073\/pnas.2418306122","volume":"122","author":"Q Zhu","year":"2025","unstructured":"Zhu Q, Yu C, Chen Y, Luo W, Li M, Zou J, et al. Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and \u03b2-elemene combination therapy. Proc Natl Acad Sci. 2025;122(11):e2418306122.","journal-title":"Proc Natl Acad Sci"},{"issue":"12Supplement","key":"2712_CR256","doi-asserted-by":"publisher","first-page":"B51","DOI":"10.1158\/2326-6074.TUMIMM22-B51","volume":"10","author":"MA Saad","year":"2022","unstructured":"Saad MA, Morala JN, Mai Z, Hasan T. Abstract B51: Photodynamic therapy modulates extracellular matrix and induces anti-tumor immune responses in an orthotopic pancreatic cancer model. Cancer immunol res. 2022;10(12Supplement):B51\u2013B.","journal-title":"Cancer immunol res"},{"key":"2712_CR257","doi-asserted-by":"crossref","unstructured":"Thiruppathi J, Vijayan V, Park I-K, Lee SE, Rhee JH. Enhancing cancer immunotherapy with photodynamic therapy and nanoparticle: making tumor microenvironment hotter to make immunotherapeutic work better. Front Immunol 2024;15:2024.","DOI":"10.3389\/fimmu.2024.1375767"},{"issue":"11","key":"2712_CR258","doi-asserted-by":"publisher","first-page":"7573","DOI":"10.1021\/acs.nanolett.9b00859","volume":"19","author":"G Obaid","year":"2019","unstructured":"Obaid G, Bano S, Mallidi S, Broekgaarden M, Kuriakose J, Silber Z, et al. Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towards Conquering Desmoplasia? Nano Lett. 2019;19(11):7573\u201387.","journal-title":"Nano Lett"},{"issue":"5","key":"2712_CR259","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1021\/acsnano.3c07002","volume":"18","author":"C Qu","year":"2024","unstructured":"Qu C, Yuan H, Tian M, Zhang X, Xia P, Shi G, et al. Precise Photodynamic Therapy by Midkine Nanobody-Engineered Nanoparticles Remodels the Microenvironment of Pancreatic Ductal Adenocarcinoma and Potentiates the Immunotherapy. ACS Nano. 2024;18(5):4019\u201337.","journal-title":"ACS Nano"},{"issue":"6","key":"2712_CR260","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1021\/acsnano.4c16329","volume":"19","author":"S Xu","year":"2025","unstructured":"Xu S, Xie X, He P, Zhu S, Li X, Chen Q, et al. Nitric oxide-producing multiple functional nanoparticle remodeling tumor microenvironment for synergistic photodynamic immunotherapy against hypoxic tumor. ACS Nano. 2025;19(6):6371\u201387.","journal-title":"ACS Nano"},{"key":"2712_CR261","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jconrel.2020.12.039","volume":"330","author":"Y Jang","year":"2021","unstructured":"Jang Y, Kim H, Yoon S, Lee H, Hwang J, Jung J, et al. Exosome-based photoacoustic imaging guided photodynamic and immunotherapy for the treatment of pancreatic cancer. J Controlled Release. 2021;330:293\u2013304.","journal-title":"J Controlled Release"},{"key":"2712_CR262","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.actbio.2021.10.048","volume":"138","author":"M Wang","year":"2022","unstructured":"Wang M, Li Y, Wang M, Liu K, Hoover AR, Li M, et al. Synergistic interventional photothermal therapy and immunotherapy using an iron oxide nanoplatform for the treatment of pancreatic cancer. Acta Biomater. 2022;138:453\u201362.","journal-title":"Acta Biomater"},{"key":"2712_CR263","doi-asserted-by":"crossref","unstructured":"Chick RC, Gunderson AJ, Rahman S, Cloyd JM. Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results. Cancers. 2023;15(15):3967.","DOI":"10.3390\/cancers15153967"},{"key":"2712_CR264","doi-asserted-by":"publisher","first-page":"175883591881628","DOI":"10.1177\/1758835918816281","volume":"10","author":"K Young","year":"2018","unstructured":"Young K, Hughes DJ, Cunningham D, Starling N. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. Ther Adv Med Oncol. 2018;10:1758835918816281.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"2712_CR265","first-page":"472","volume":"6","author":"X Zhang","year":"2021","unstructured":"Zhang X, Tang J, Li C, Lu Y, Cheng L, Liu J. A targeting black phosphorus nanoparticle based immune cells nano-regulator for photodynamic\/photothermal and photo-immunotherapy. Bioact mater. 2021;6(2):472\u201389.","journal-title":"Bioact mater"},{"issue":"15","key":"2712_CR266","doi-asserted-by":"publisher","first-page":"2204890","DOI":"10.1002\/advs.202204890","volume":"10","author":"X Shi","year":"2023","unstructured":"Shi X, Shu L, Wang M, Yao J, Yao Q, Bian S, et al. Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models. Adv Sci. 2023;10(15):2204890.","journal-title":"Adv Sci"},{"key":"2712_CR267","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.actbio.2023.08.007","volume":"169","author":"R Wang","year":"2023","unstructured":"Wang R, Hong K, Zhang Q, Cao J, Huang T, Xiao Z, et al. A nanodrug simultaneously inhibits pancreatic stellate cell activation and regulatory T cell infiltration to promote the immunotherapy of pancreatic cancer. Acta Biomater. 2023;169:451\u201363.","journal-title":"Acta Biomater"},{"key":"2712_CR268","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2018.09.031","volume":"290","author":"DF Mardhian","year":"2018","unstructured":"Mardhian DF, Storm G, Bansal R, Prakash J. Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo. J Control Release. 2018;290:1\u201310.","journal-title":"J Control Release"},{"issue":"1","key":"2712_CR269","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1038\/s41467-018-05906-x","volume":"9","author":"X Han","year":"2018","unstructured":"Han X, Li Y, Xu Y, Zhao X, Zhang Y, Yang X, et al. Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem. Nat Commun. 2018;9(1):3390.","journal-title":"Nat Commun"},{"issue":"1","key":"2712_CR270","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1021\/acsnano.4c11514","volume":"19","author":"M Ding","year":"2025","unstructured":"Ding M, Zong Q, Zhang D, Ullah I, Zhang X, Liang W, et al. Self-Adaptive Nanocarriers Overcome Multiple Physiological Barriers to Boosting Chemotherapy of Orthotopic Pancreatic Cancer. ACS Nano. 2025;19(1):662\u201379.","journal-title":"ACS Nano"},{"issue":"29","key":"2712_CR271","doi-asserted-by":"publisher","first-page":"e2201931","DOI":"10.1002\/advs.202201931","volume":"9","author":"S Bian","year":"2022","unstructured":"Bian S, Dong H, Zhao L, Li Z, Chen J, Zhu X, et al. Antihypertension nanoblockers increase intratumoral perfusion of sequential cytotoxic nanoparticles to enhance chemotherapy efficacy against pancreatic cancer. Adv Sci. 2022;9(29):e2201931.","journal-title":"Adv Sci"},{"issue":"11","key":"2712_CR272","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1021\/nn404083m","volume":"7","author":"H Meng","year":"2013","unstructured":"Meng H, Zhao Y, Dong J, Xue M, Lin YS, Ji Z, et al. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano. 2013;7(11):10048\u201365.","journal-title":"ACS Nano"},{"key":"2712_CR273","doi-asserted-by":"crossref","unstructured":"Yang M, Tong Y, Yin S, Zhang H, Huang X, Yuan K et al. Microthrombi targeted nano-micelle synchronizing endothelial gap opening and matrix decompression for augmenting drug perfusion within pancreatic cancer. Acta Pharm Sin B. 2025;16(6):3861\u201375.","DOI":"10.1016\/j.apsb.2025.12.037"},{"issue":"8","key":"2712_CR274","doi-asserted-by":"publisher","first-page":"7928","DOI":"10.1021\/acsnano.4c14969","volume":"19","author":"J Wu","year":"2025","unstructured":"Wu J, Cheng Y, Qian K, Yang P, Zhou L, Xu M, et al. siRNA-encapsulated biomimetic liposomes effectively inhibit tumor cells\u2019 hexosamine biosynthesis pathway for attenuating hyaluronan barriers to pancreatic cancer chemotherapy. ACS Nano. 2025;19(8):7928\u201347.","journal-title":"ACS Nano"},{"issue":"36","key":"2712_CR275","doi-asserted-by":"publisher","first-page":"40535","DOI":"10.1021\/acsami.2c08951","volume":"14","author":"J Luo","year":"2022","unstructured":"Luo J, Cao J, Ma G, Wang X, Sun Y, Zhang C, et al. Collagenase-loaded H-TiO(2) nanoparticles enhance ultrasound imaging-guided sonodynamic therapy in a pancreatic carcinoma xenograft model via digesting stromal barriers. ACS Appl Mater Interfaces. 2022;14(36):40535\u201345.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"0","key":"2712_CR276","first-page":"2823","volume":"19","author":"M Wang","year":"2024","unstructured":"Wang M, Xue W, Yuan H, Wang Z, Yu L. Nano-Drug Delivery Systems Targeting CAFs: A Promising Treatment for Pancreatic Cancer. Int J Nanomed. 2024;19(0):2823\u201349.","journal-title":"Int J Nanomed"},{"issue":"2","key":"2712_CR277","first-page":"75","volume":"19","author":"BC Chapman","year":"2018","unstructured":"Chapman BC, Gleisner A, Rigg D, Messersmith W, Paniccia A, Meguid C, et al. Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma. Jop. 2018;19(2):75\u201385.","journal-title":"Jop"},{"issue":"3","key":"2712_CR278","first-page":"209","volume":"18","author":"M Wojtasik","year":"2025","unstructured":"Wojtasik M, Kuehn RB, Gaska T, Reichert D, Brinkmann L, Depenbusch R, et al. EffiXane \u2014 Non-interventional study on safety and effectiveness of nab-paclitaxel (Abraxane\u00ae) + gemcitabine as first-line treatment of metastatic PDAC in a daily routine setting. memo - Magazine Eur Med Oncol. 2025;18(3):209\u201315.","journal-title":"memo - Magazine Eur Med Oncol"},{"issue":"5","key":"2712_CR279","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1007\/s13346-020-00884-4","volume":"11","author":"X Wang","year":"2021","unstructured":"Wang X, Liu Y, Xu W, Jia L, Chi D, Yu J, et al. Irinotecan and berberine co-delivery liposomes showed improved efficacy and reduced intestinal toxicity compared with Onivyde for pancreatic cancer. Drug Delivery Transl Res. 2021;11(5):2186\u201397.","journal-title":"Drug Delivery Transl Res"},{"issue":"10","key":"2712_CR280","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s40265-020-01336-6","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton JE. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma. Drugs. 2020;80(10):1007\u201318.","journal-title":"Drugs"},{"issue":"1","key":"2712_CR281","doi-asserted-by":"publisher","first-page":"8696","DOI":"10.1038\/s41467-025-63718-2","volume":"16","author":"VS Kalluri","year":"2025","unstructured":"Kalluri VS, Smaglo BG, Mahadevan KK, Kirtley ML, McAndrews KM, Mendt M, et al. Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Nat Commun. 2025;16(1):8696.","journal-title":"Nat Commun"},{"issue":"2","key":"2712_CR282","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/1078-0432.CCR-23-1821","volume":"30","author":"V Ganju","year":"2024","unstructured":"Ganju V, Marx G, Pattison S, Amaro-Mugridge NB, Zhao J-T, Williams BRG, et al. Phase I\/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells. Clin Cancer Res. 2024;30(2):304\u201314.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2712_CR283","doi-asserted-by":"publisher","first-page":"31602","DOI":"10.1038\/s41598-025-16848-y","volume":"15","author":"N Qin","year":"2025","unstructured":"Qin N, Bian Z, Chen J. Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks. Sci Rep. 2025;15(1):31602.","journal-title":"Sci Rep"},{"issue":"1","key":"2712_CR284","doi-asserted-by":"publisher","first-page":"e2350756","DOI":"10.1001\/jamanetworkopen.2023.50756","volume":"7","author":"F Nichetti","year":"2024","unstructured":"Nichetti F, Rota S, Ambrosini P, Pircher C, Gusmaroli E, Droz Dit Busset M, et al. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7(1):e2350756\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"10409","key":"2712_CR285","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardi\u00e8re C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272\u201381.","journal-title":"Lancet"},{"issue":"5","key":"2712_CR286","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/annonc\/mdr379","volume":"23","author":"JM L\u00f6hr","year":"2012","unstructured":"L\u00f6hr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol. 2012;23(5):1214\u201322.","journal-title":"Ann Oncol"},{"key":"2712_CR287","doi-asserted-by":"publisher","first-page":"v321","DOI":"10.1093\/annonc\/mdz247.160","volume":"30","author":"LT Chen","year":"2019","unstructured":"Chen LT, Hitre E, Lee WJ, Bai LY, Papa\u00ef Z, Kang SY, et al. A randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and\/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment. Ann Oncol. 2019;30:v321.","journal-title":"Ann Oncol"},{"key":"2712_CR288","first-page":"66","volume":"33","author":"AF Bagley","year":"2022","unstructured":"Bagley AF, Ludmir EB, Maitra A, Minsky BD, Li Smith G, Das P, et al. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol. 2022;33:66\u20139.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"2712_CR289","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1016\/j.ijrobp.2022.07.1124","volume":"114","author":"G Fuentes","year":"2022","unstructured":"Fuentes G, Rodriguez MJ, Matthew G, De Gracia B, Katz MHG, Ikoma N, et al. Trial in Progress: 2019\u2009\u2013\u20091001 A Phase I Study of NBTXR3 Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Ductal Adenocarcinoma (LAPC or BRPC). Int J Radiat Oncol Biol Phys. 2022;114(3):e202.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2712_CR290","doi-asserted-by":"crossref","unstructured":"Varghese AM, Ang C, Dimaio CJ, Javle MM, Gutierrez M, Yarom N et al. A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT). J Clin Oncol. 2020;38(15_suppl):TPS4672\u2013TPS.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4672"},{"issue":"2","key":"2712_CR291","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/sj.bjc.6603855","volume":"97","author":"T Hamaguchi","year":"2007","unstructured":"Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer. 2007;97(2):170\u20136.","journal-title":"Br J Cancer"},{"issue":"24","key":"2712_CR292","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1158\/1078-0432.CCR-10-0978","volume":"16","author":"SK Libutti","year":"2010","unstructured":"Libutti SK, Paciotti GF, Byrnes AA, Alexander HR Jr., Gannon WE, Walker M, et al. Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin Cancer Res. 2010;16(24):6139\u201349.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2712_CR293","first-page":"1201","volume":"15","author":"GP Stathopoulos","year":"2006","unstructured":"Stathopoulos GP, Boulikas T, Vougiouka M, Rigatos SK, Stathopoulos JG. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep. 2006;15(5):1201\u20134.","journal-title":"Oncol Rep"},{"issue":"1","key":"2712_CR294","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-024-01948-4","volume":"9","author":"J Cui","year":"2024","unstructured":"Cui J, Qin S, Zhou Y, Zhang S, Sun X, Zhang M, et al. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial. Signal Transduct Target ther. 2024;9(1):248.","journal-title":"Signal Transduct Target ther"},{"issue":"4","key":"2712_CR295","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317\u201327.","journal-title":"N Engl J Med"},{"issue":"18","key":"2712_CR296","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","volume":"394","author":"M Wolpin Brian","year":"2026","unstructured":"Wolpin Brian M, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, et al. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. N Engl J Med. 2026;394(18):1790\u2013802.","journal-title":"N Engl J Med"},{"issue":"6","key":"2712_CR297","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-25-3189","volume":"32","author":"B Alagesan","year":"2026","unstructured":"Alagesan B, Varghese AM, Ang C, Gutierrez M, Kamar M, Passhak M, et al. A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D\/V in Locally Advanced Pancreatic Cancer. Clin Cancer Res. 2026;32(6):1059\u201367.","journal-title":"Clin Cancer Res"},{"key":"2712_CR298","doi-asserted-by":"publisher","first-page":"100793","DOI":"10.1016\/j.neo.2022.100793","volume":"30","author":"T Seki","year":"2022","unstructured":"Seki T, Saida Y, Kishimoto S, Lee J, Otowa Y, Yamamoto K, et al. PEGPH20, a PEGylated human hyaluronidase, induces radiosensitization by reoxygenation in pancreatic cancer xenografts. A molecular imaging study. Neoplasia. 2022;30:100793.","journal-title":"Neoplasia"},{"issue":"4","key":"2712_CR299","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41416-019-0683-3","volume":"122","author":"A De Jesus-Acosta","year":"2020","unstructured":"De Jesus-Acosta A, Sugar EA, O\u2019Dwyer PJ, Ramanathan RK, Von Hoff DD, Rasheed Z, et al. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Br J Cancer. 2020;122(4):498\u2013505.","journal-title":"Br J Cancer"},{"issue":"9","key":"2712_CR300","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer \u2014 clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17(9):527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"Pt 1","key":"2712_CR301","doi-asserted-by":"publisher","first-page":"116870","DOI":"10.1016\/j.envres.2023.116870","volume":"237","author":"M Neetika, Sharma","year":"2023","unstructured":"Neetika, Sharma M, Thakur P, Gaur P, Rani GM, Rustagi S, et al. Cancer treatment and toxicity outlook of nanoparticles. Environ Res. 2023;237(Pt 1):116870.","journal-title":"Environ Res"},{"issue":"1","key":"2712_CR302","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2217\/nnm.15.188","volume":"11","author":"C Corbo","year":"2016","unstructured":"Corbo C, Molinaro R, Parodi A, Toledano Furman NE, Salvatore F, Tasciotti E. The Impact of Nanoparticle Protein Corona on Cytotoxicity, Immunotoxicity and Target Drug Delivery. Nanomedicine. 2016;11(1):81\u2013100.","journal-title":"Nanomedicine"},{"issue":"null","key":"2712_CR303","first-page":"97","volume":"10","author":"YK Lee","year":"2015","unstructured":"Lee YK, Choi E-J, Webster TJ, Kim S-H, Khang D. Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity. Int J Nanomed. 2015;10(null):97\u2013113.","journal-title":"Int J Nanomed"},{"issue":"3","key":"2712_CR304","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s13346-022-01262-y","volume":"13","author":"DA Dri","year":"2023","unstructured":"Dri DA, Rinaldi F, Carafa M, Marianecci C. Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes. Drug Delivery Transl Res. 2023;13(3):757\u201369.","journal-title":"Drug Delivery Transl Res"},{"issue":"12","key":"2712_CR305","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1016\/j.xphs.2024.09.005","volume":"113","author":"JD Clogston","year":"2024","unstructured":"Clogston JD, Foss W, Harris D, Oberoi H, Pan J, Pu E, et al. Current state of nanomedicine drug products: An industry perspective. J Pharm Sci. 2024;113(12):3395\u2013405.","journal-title":"J Pharm Sci"},{"issue":"1","key":"2712_CR306","doi-asserted-by":"publisher","first-page":"e1531","DOI":"10.1002\/wnan.1531","volume":"11","author":"B Halamoda-Kenzaoui","year":"2019","unstructured":"Halamoda-Kenzaoui B, Holzwarth U, Roebben G, Bogni A, Bremer-Hoffmann S. Mapping of the available standards against the regulatory needs for nanomedicines. WIREs Nanomed Nanobiotechnol. 2019;11(1):e1531.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"2712_CR307","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2024.04.010","volume":"180","author":"EB Souto","year":"2024","unstructured":"Souto EB, Blanco-Llamero C, Krambeck K, Kiran NS, Yashaswini C, Postwala H, et al. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives. Acta Biomater. 2024;180:1\u201317.","journal-title":"Acta Biomater"},{"issue":"5","key":"2712_CR308","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3390\/cancers12051327","volume":"12","author":"PL Garcia","year":"2020","unstructured":"Garcia PL, Miller AL, Yoon KJ. Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. Cancers. 2020;12(5):1327. p.].","journal-title":"Cancers"},{"issue":"2","key":"2712_CR309","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21037\/cco.2019.02.04","volume":"8","author":"Y Wang","year":"2019","unstructured":"Wang Y, Cui J, Wang L. Patient-derived xenografts: a valuable platform for clinical and preclinical research in pancreatic cancer. Chin CliN Oncol. 2019;8(2):17.","journal-title":"Chin CliN Oncol"},{"issue":"6","key":"2712_CR310","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.ajpath.2016.02.009","volume":"186","author":"K Pham","year":"2016","unstructured":"Pham K, Delitto D, Knowlton AE, Hartlage ER, Madhavan R, Gonzalo DH, et al. Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. Am J Pathol. 2016;186(6):1537\u201346.","journal-title":"Am J Pathol"},{"issue":"4","key":"2712_CR311","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.trecan.2016.03.004","volume":"2","author":"LA Baker","year":"2016","unstructured":"Baker LA, Tiriac H, Clevers H, Tuveson DA. Modeling Pancreatic Cancer with Organoids. Trends Cancer. 2016;2(4):176\u201390.","journal-title":"Trends Cancer"},{"issue":"6444","key":"2712_CR312","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1126\/science.aaw6985","volume":"364","author":"D Tuveson","year":"2019","unstructured":"Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science. 2019;364(6444):952\u20135.","journal-title":"Science"},{"issue":"28","key":"2712_CR313","doi-asserted-by":"publisher","first-page":"2214937","DOI":"10.1002\/adfm.202214937","volume":"33","author":"H Chen","year":"2023","unstructured":"Chen H, Song H, Luo Y, Li C, Wang Y, Liu J, et al. Transcytosis Mediated Deep Tumor Penetration for Enhanced Chemotherapy and Immune Activation of Pancreatic Cancer. Adv Funct Mater. 2023;33(28):2214937.","journal-title":"Adv Funct Mater"},{"issue":"8","key":"2712_CR314","doi-asserted-by":"publisher","first-page":"7184","DOI":"10.1021\/acsnano.5c20618","volume":"20","author":"J-E Hwang","year":"2026","unstructured":"Hwang J-E, Jeon M, Yim H, Park J, Kim H-S, Lee S, et al. Collagenase-Functionalized Liposomes Overcome Stromal Barriers in Pancreatic Cancer. ACS Nano. 2026;20(8):7184\u2013204.","journal-title":"ACS Nano"},{"issue":"19","key":"2712_CR315","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1039\/D5NA00513B","volume":"7","author":"L Peng","year":"2025","unstructured":"Peng L, Liang Y, Guo X, Zhang Q, Gao Z, Kong X, et al. Nanomedicine breakthroughs overcoming pancreatic cancer drug resistance through precision nano-interventions. Nanoscale Adv. 2025;7(19):5888\u2013904.","journal-title":"Nanoscale Adv"},{"issue":"23","key":"2712_CR316","doi-asserted-by":"publisher","first-page":"21385","DOI":"10.1021\/acsnano.5c01280","volume":"19","author":"G Chen","year":"2025","unstructured":"Chen G, Li T, Duan R, Liang W, Li B, Xie X, et al. Cognate Nanovaccine Promotes Tertiary Lymphoid Structures Function and Strengthens Immune Cell Cross-Talk by Targeting Exhausted T Cells in Nonimmunogenic Cancers. ACS Nano. 2025;19(23):21385\u201399.","journal-title":"ACS Nano"},{"issue":"8","key":"2712_CR317","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41571-024-00896-w","volume":"21","author":"C Nevala-Plagemann","year":"2024","unstructured":"Nevala-Plagemann C, Garrido-Laguna I. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nat. Rev Clin Oncol. 2024;21(8):567\u20138.","journal-title":"Rev Clin Oncol"},{"issue":"11","key":"2712_CR318","doi-asserted-by":"publisher","first-page":"5862","DOI":"10.1039\/D3CS00602F","volume":"53","author":"JN Rahmat","year":"2024","unstructured":"Rahmat JN, Liu J, Chen T, Li Z, Zhang Y. Engineered biological nanoparticles as nanotherapeutics for tumor immunomodulation. Chem Soc Rev. 2024;53(11):5862\u2013903.","journal-title":"Chem Soc Rev"},{"key":"2712_CR319","doi-asserted-by":"crossref","unstructured":"Perko N, Mousa SA. Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting. Cancers. 2022;14(12):2879.","DOI":"10.3390\/cancers14122879"},{"key":"2712_CR320","doi-asserted-by":"publisher","first-page":"116685","DOI":"10.1016\/j.bcp.2024.116685","volume":"232","author":"S Escalera-Anzola","year":"2025","unstructured":"Escalera-Anzola S, Rosado M, Yang Y, Parra-Sanchez D, Pedro-Liberal CS, Acedo P. Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy. Biochem Pharmacol. 2025;232:116685.","journal-title":"Biochem Pharmacol"},{"key":"2712_CR321","doi-asserted-by":"crossref","unstructured":"T\u00fcreli NG, T\u00fcreli AE. Chapter 11 - Upscaling and GMP production of pharmaceutical drug delivery systems. In: Shegokar R, editor. Drug Delivery Trends. 2020;3:215\u201329.","DOI":"10.1016\/B978-0-12-817870-6.00011-0"},{"issue":"9","key":"2712_CR322","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.7150\/thno.14858","volume":"6","author":"D Liu","year":"2016","unstructured":"Liu D, Yang F, Xiong F, Gu N. The Smart Drug Delivery System and Its Clinical Potential. Theranostics. 2016;6(9):1306\u201323.","journal-title":"Theranostics"},{"key":"2712_CR323","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2014.03.053","volume":"190","author":"AC Anselmo","year":"2014","unstructured":"Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Controlled Release. 2014;190:15\u201328.","journal-title":"J Controlled Release"},{"issue":"1","key":"2712_CR324","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1021\/nn900002m","volume":"3","author":"OC Farokhzad","year":"2009","unstructured":"Farokhzad OC, Langer R. Impact of Nanotechnology on Drug Delivery. ACS Nano. 2009;3(1):16\u201320.","journal-title":"ACS Nano"},{"issue":"9","key":"2712_CR325","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41551-021-00698-w","volume":"5","author":"AM Vargason","year":"2021","unstructured":"Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021;5(9):951\u201367.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"2712_CR326","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/gutjnl-2016-312432","volume":"67","author":"J Mayerle","year":"2018","unstructured":"Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut. 2018;67(1):128.","journal-title":"Gut"},{"issue":"16","key":"2712_CR327","doi-asserted-by":"publisher","first-page":"6931","DOI":"10.7150\/thno.77949","volume":"12","author":"B Huang","year":"2022","unstructured":"Huang B, Huang H, Zhang S, Zhang D, Shi Q, Liu J, et al. Artificial intelligence in pancreatic cancer. Theranostics. 2022;12(16):6931\u201354.","journal-title":"Theranostics"},{"issue":"47","key":"2712_CR328","doi-asserted-by":"publisher","first-page":"32279","DOI":"10.1021\/acsnano.4c14832","volume":"18","author":"X Chen","year":"2024","unstructured":"Chen X, Buriak JM, Salanne M, Xin H. Nano & AI: A Nobel Partnership. ACS Nano. 2024;18(47):32279\u201382.","journal-title":"ACS Nano"},{"issue":"13","key":"2712_CR329","doi-asserted-by":"publisher","first-page":"1901989","DOI":"10.1002\/adma.201901989","volume":"32","author":"O Adir","year":"2020","unstructured":"Adir O, Poley M, Chen G, Froim S, Krinsky N, Shklover J, et al. Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine. Adv Mater. 2020;32(13):1901989.","journal-title":"Adv Mater"},{"key":"2712_CR330","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.actbio.2022.03.050","volume":"145","author":"T Zhao","year":"2022","unstructured":"Zhao T, Zhang R, He Q, Zhou H, Song X, Gong T, et al. Partial ligand shielding nanoparticles improve pancreatic ductal adenocarcinoma treatment via a multifunctional paradigm for tumor stroma reprogramming. Acta Biomater. 2022;145:122\u201334.","journal-title":"Acta Biomater"},{"issue":"8","key":"2712_CR331","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: Advances and challenges. Cell. 2023;186(8):1729\u201354.","journal-title":"Cell"},{"issue":"7","key":"2712_CR332","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","volume":"21","author":"EJ Sayour","year":"2024","unstructured":"Sayour EJ, Boczkowski D, Mitchell DA, Nair SK. Cancer mRNA vaccines: clinical advances and future opportunities. Nat Rev Clin Oncol. 2024;21(7):489\u2013500.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2712_CR333","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-021-01310-0","volume":"20","author":"X Huang","year":"2021","unstructured":"Huang X, Zhang G, Tang T, Liang T. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Mol Cancer. 2021;20(1):44.","journal-title":"Mol Cancer"},{"issue":"1","key":"2712_CR334","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1038\/s41467-025-61242-x","volume":"16","author":"H Zhang","year":"2025","unstructured":"Zhang H, Santana-Codina N, Yu Q, Poupault C, Campos C, Qin X, et al. De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer. Nat Commun. 2025;16(1):6987.","journal-title":"Nat Commun"},{"key":"2712_CR335","doi-asserted-by":"crossref","unstructured":"Doffo J, Bamopoulos SA, K\u00f6se H, Orben F, Zang C, Pons M et al. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proc. Natl. Acad. Sci. 2022;119(9):e2105691119.","DOI":"10.1073\/pnas.2105691119"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02712-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02712-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:02:37Z","timestamp":1792072957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02712-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":335,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2712"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02712-8","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All of the authors are aware of and agree to the content of the paper.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"239"}}